{"text": "Similarly , five ( 0.04 % ) of 11 765 patients had a fatal bleeding episode , of whom four ( 80 % ) received placebo or observation .", "label": "", "metadata": {}, "score": "34.250725"}
{"text": "All remaining studies enrolled only patients with unprovoked VTE ( table 1 ) .Web appendix 3 reports on quality assessment .Overall , a low risk of bias was identified .", "label": "", "metadata": {}, "score": "35.321125"}
{"text": "9 Selection of a strategy before randomisation provides the opportunity to do a proper statistical comparison between the groups .Methods .Design overview .The PLATO trial enrolled 18 624 patients from 43 countries between October 2006 and July 2008 .", "label": "", "metadata": {}, "score": "38.395477"}
{"text": "We retrieved INRs from the day the event had occurred in 278 cases ( 91 % ) .Another 10 INRs could be obtained from the medical records of the anticoagulation clinic because they had been measured within 8 days before the event .", "label": "", "metadata": {}, "score": "39.166447"}
{"text": "About one - third underwent surgery .A minority had neurologic disorders .Complete clinical information could be obtained in 3188 admissions ( 99 % ) .", "label": "", "metadata": {}, "score": "40.60678"}
{"text": "The analysis on recurrent VTE included 11 999 patients .One trial was excluded from the recurrent VTE analyses because the number of events occurring while patients were receiving VKA could not be extracted from the original manuscript .", "label": "", "metadata": {}, "score": "42.460495"}
{"text": "Results 12 articles met our inclusion criteria , with 11 999 patients evaluated for efficacy and 12 167 for safety .All treatments reduced the risk of recurrent venous thromboembolism .", "label": "", "metadata": {}, "score": "42.789803"}
{"text": "In the overall PLATO population , 7955 patients had non - ST elevation acute coronary artery syndrome as their final diagnosis .Among these , 2910 ( 36.6 % ) patients were intended for non - invasive management at the time of randomisation .", "label": "", "metadata": {}, "score": "42.963364"}
{"text": "The patients in the GISSI - Prevenzione trial were also well treated with antithrombotic and antihypertensive drugs but only 29 % received statins ( 8 ) .", "label": "", "metadata": {}, "score": "43.972"}
{"text": "In the second stage of the review process , two medical specialists independently reviewed the records screened positive by the nurses in stage one ( 4,317 patient records ) .", "label": "", "metadata": {}, "score": "44.32628"}
{"text": "Patients .The PLATO trial recruited 18 624 patients with acute coronary syndrome ( with or without ST elevation ) from 862 centres in 43 countries between October 2006 and July 2008 .", "label": "", "metadata": {}, "score": "44.91043"}
{"text": "Results A total of 3226 hospital admissions were reported , 306 owing to an untoward event .Conclusion Our study suggests target INRs of 3.0 for patients with mechanical heart valve prostheses and atrial fibrillation and 3.5 after myocardial infarction as a starting point in future clinical trials .", "label": "", "metadata": {}, "score": "45.182915"}
{"text": "Surgical AEs occurred in 3.6 % of hospital admissions and represented 65 % of all AEs .Forty - one percent of the surgical AEs was considered to be preventable .", "label": "", "metadata": {}, "score": "45.34065"}
{"text": "All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment [ Time Frame :", "label": "", "metadata": {}, "score": "45.39003"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : Yes ] .All events were adjudicated and confirmed by a central independent adjudication committee ( CIAC ) blinded to treatment .", "label": "", "metadata": {}, "score": "45.56591"}
{"text": "Table 5 .Causes and prevention strategies .The surgeon reviewers selected 653 causal factors for the 367 surgical AEs found in this study .Causal factors of surgical AEs were judged to be predominantly human ( 65.2 % ) and patient - related ( 35.3 % ) , and less often organizational ( 12.7 % ) , and technical ( 4.4 % )", "label": "", "metadata": {}, "score": "46.0653"}
{"text": "32 Analyses were performed using WinBUGS software ( MRC Biostatistics Unit ) .A network meta - analysis also requires that studies are sufficiently similar in order to pool their results .", "label": "", "metadata": {}, "score": "46.080986"}
{"text": "After adjustment , these three n-3 fatty acids together reduced this combined end point by 72 % ( cumulative incidence at median follow - up 2.6 vs. 8.5 % , Fig . 1 C ; 0.28 ; 0.11 - 0.71 ) .", "label": "", "metadata": {}, "score": "46.09458"}
{"text": "The panel members - a neurologist ( W.L.E.M.B. ) , cardiologist ( E.E.v.d .W. ) , internist , and clinical epidemiologist ( F.R.R.)-were at all times blinded to the intensity of oral anticoagulation at the time of the event .", "label": "", "metadata": {}, "score": "46.11895"}
{"text": "Definitions of bleeding used in the trial have been previously published .9 An independent central adjudication committee , unaware of the group assignments , adjudicated all primary and secondary end points and major and minor bleeding events .", "label": "", "metadata": {}, "score": "46.15691"}
{"text": "Results .In our literature search , we identified 636 citations and deemed 13 records as potentially eligible ( web appendix 2 ) .16 17 18 19 20 35 36 37 38 39 40 41 Two studies initially identified as abstracts were published within the same article at the time of analysis ( 12 articles ) .", "label": "", "metadata": {}, "score": "46.167587"}
{"text": "Approximately 50 % of the AEs were judged to be preventable .Most of the AEs resulted in minor or temporary disability , but a proportion of the AEs , 4 % to 21 % , contributed to death .", "label": "", "metadata": {}, "score": "46.45112"}
{"text": "PLATO patients were predominantly male ( 72 % ) and Caucasian ( 92 % ) .The study 's primary endpoint was the composite of first occurrence of cardiovascular death , non - fatal MI ( excluding silent MI ) , or non - fatal stroke .", "label": "", "metadata": {}, "score": "46.54362"}
{"text": "More than two - thirds of the injuries related to a mechanical / physical or chemical cause was judged to be preventable .The surgeon reviewers noticed that an inaccurately performed procedure was a major contributing factor to injuries by puncture or perforation of other organs , such as nerves , vessels and bowels .", "label": "", "metadata": {}, "score": "46.70256"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : Yes ] .All pre - defined vascular events ( acute coronary syndromes , ischemic stroke , transient ischemic attack , non - central nervous system systemic embolism and vascular death ) were adjudicated / confirmed by a central independent adjudication committee blinded to treatment , based on results / films / images of confirmatory testing , and/or case summaries .", "label": "", "metadata": {}, "score": "46.715477"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : No ] .All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .", "label": "", "metadata": {}, "score": "46.911118"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : No ] .All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .", "label": "", "metadata": {}, "score": "46.911118"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : No ] .All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .", "label": "", "metadata": {}, "score": "46.911118"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : No ] .All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .", "label": "", "metadata": {}, "score": "46.911118"}
{"text": "( Virtually ) certain evidence of management causation .Causation scores of 4 to 6 were classified as adverse events .The degree of preventability of the adverse events was measured on a 6-point scale : .", "label": "", "metadata": {}, "score": "46.949295"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : Yes ] .All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .", "label": "", "metadata": {}, "score": "46.95923"}
{"text": "Eleven hemorrhages ( 3 intracranial and 8 extracranial ) were life threatening , as were 25 myocardial infarctions .The incidence of life - threatening and fatal events combined therefore became 0.5 per 100 patient - years ( 95 % CI , 0.3 - 0.8 ) for hemorrhage and 1.2 per 100 patient - years ( 95 % CI , 0.8 - 1.6 ) for arterial thromboembolism .", "label": "", "metadata": {}, "score": "46.95964"}
{"text": "Most patients ( 2820 [ 67 % ] ) were already prescribed vitamin K antagonists when the study started , and 1382 patients ( 33 % ) entered the study later on when they started treatment .", "label": "", "metadata": {}, "score": "47.19044"}
{"text": "The incidence of nonfatal bleeding events was 3.1 per 100 patient - years ( 95 % CI , 2.1 - 4.2 ) .Nine patients experienced a thromboembolic event ( 0.8 per 100 patient - years ; 95 % CI , 0.4 - 1.4 ) , of which 2 myocardial infarctions were fatal ( 0.2 per 100 patient - years ; 95 % CI , 0.0 - 0.5 ) .", "label": "", "metadata": {}, "score": "47.44211"}
{"text": "Definitions of these events were adopted from previous studies .13 , 16 Major hemorrhage consisted of intracranial , spinal , and extracranial bleeding events .", "label": "", "metadata": {}, "score": "47.845943"}
{"text": "Other sex - hormonal adverse reactions , including sex organ malignancies , did not differ between the two treatment groups in PLATO .Lab abnormalities .", "label": "", "metadata": {}, "score": "47.90151"}
{"text": "Our study showed that infection , bleeding and injury due to a mechanical / physical or chemical cause formed the largest group of injuries as a result of surgical AEs , reflecting the results of patient record review studies of more than ten years ago [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "48.028915"}
{"text": "For more than 70 % of the surgical AEs , quality assurance / peer review was selected as a potential prevention strategy .Other frequently selected prevention strategies were training ( 58.9 % ) , evaluation ( 51.4 % ) , and improving procedures ( 40.6 % ) .", "label": "", "metadata": {}, "score": "48.047707"}
{"text": "Results .Three additional trials were identified by a hand search of the bibliography of the remaining articles . 8 17 18 A total of nine trials , reported in 12 publications , were assessed in full text .", "label": "", "metadata": {}, "score": "48.35697"}
{"text": "Incidence and preventability .In the 7,926 reviewed patient records , 744 AEs were found .Using the weighting factor for over - representation of deceased patients and hospital type , the results showed that surgical AEs occurred in 3.6 % of hospital admissions and accounted for 64.5 % of all AEs ( Table 1 ) .", "label": "", "metadata": {}, "score": "48.38154"}
{"text": "Three members of the Endpoint Adjudication Committee who were blinded for patient identity , treating physician , and allocated treatment coded the fatal events independently according to the 10th revision of the International Classification of Diseases .", "label": "", "metadata": {}, "score": "48.444183"}
{"text": "Lower INRs led to higher incidence rates : from 2.6 events per 100 patient - years ( 95 % CI , 1.5 - 4.0 ) for INRs of 2.5 to 2.9 , up to 32.9 per 100 patient - years ( 95 % CI , 10.1 - 68.9 ) for INRs less than 1.5 .", "label": "", "metadata": {}, "score": "48.50476"}
{"text": "Half of the studies evaluated failed to specify whether randomisation allocation was concealed and some were relatively outdated and hardly applicable in current practice , where patterns for the management of cardiovascular risk factors in diabetes have changed .", "label": "", "metadata": {}, "score": "48.74258"}
{"text": "N Engl J Med .10.1056/NEJM199102073240605 .View Article PubMed .Michel P , Quenon JL , de Sarasqueta AM , Scemama O : Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals .", "label": "", "metadata": {}, "score": "49.08841"}
{"text": "Events were considered to be fatal when the patient died as a direct consequence of the event .All other events were considered to be serious .", "label": "", "metadata": {}, "score": "49.17891"}
{"text": "All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .Percentage of Participants With the Composite Variable Comprising Recurrent DVT , Non - fatal PE , All Cause Mortality , Strokes and Myocardial Infarctions During Observational Period [ Time Frame : 30 days observational period after last intake of study medication ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "49.43596"}
{"text": "No adjustments were made for multiple comparisons because only a priori - formulated hypotheses were tested based on animal experiments of the effects of n-3 fatty acids on atherosclerosis and cardiac arrhythmias ( 5 ) .", "label": "", "metadata": {}, "score": "49.47342"}
{"text": "Despite an intended non - invasive strategy at the time of randomisation , approximately half of the patients had coronary angiography , a third had percutaneous coronary intervention , and one tenth had coronary artery bypass grafting during the course of the study for emerging clinical indications .", "label": "", "metadata": {}, "score": "49.48528"}
{"text": "Patients were predominantly male ( 76 % ) Caucasian ( 87 % ) with a mean age 65 years , and 99.8 % of patients received prior Aspirin therapy .", "label": "", "metadata": {}, "score": "49.667458"}
{"text": "The Figure shows the INR - specific incidence rates of all combined untoward events and their 95 % CI per INR level .The lowest incidence was found at an INR of 2.5 to 2.9 : 2.0 per 100 patient - years ( 95 % CI , 0.2 - 5.7 ) .", "label": "", "metadata": {}, "score": "49.699566"}
{"text": "Events were assessed based on unexplained death for which DVT / PE could not be ruled out , results / films / images of confirmatory testing , and/or case summaries .", "label": "", "metadata": {}, "score": "49.739883"}
{"text": "We calculated INR - specific incidence rates as the ratio of the number of events that occurred at a certain INR level and the number of patient - years that this intensity level had been reached by the total patient population .", "label": "", "metadata": {}, "score": "49.778736"}
{"text": "Almost 40 % of the surgical AEs were infections , 23 % bleeding , and 22 % injury by mechanical , physical or chemical cause .", "label": "", "metadata": {}, "score": "49.802254"}
{"text": "All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .Events were assessed based on either compression ultrasound , venography , results / films / images of confirmatory testing , and/or case summaries .", "label": "", "metadata": {}, "score": "49.85571"}
{"text": "We present estimates of the end points for each treatment group as the Kaplan - Meier rates at 360 days and total number of events during follow - up .", "label": "", "metadata": {}, "score": "50.133217"}
{"text": "Data on major cardiovascular events ( death from cardiovascular causes , non - fatal myocardial infarction , non - fatal stroke , and all cause mortality ) were extracted and pooled with a random effect model .", "label": "", "metadata": {}, "score": "50.32373"}
{"text": "The incidence rate of all untoward events in patients treated after a myocardial infarction was 3.6 ( 95 % CI , 3.0 - 4.4 ) per 100 patient - years ( Table 2 ) .", "label": "", "metadata": {}, "score": "50.467487"}
{"text": "Among the studies included in this systematic review , all novel oral anticoagulants and antiplatelet drugs investigated were associated with a reduced recurrence of venous thromboembolism compared with placebo or observation .", "label": "", "metadata": {}, "score": "50.77017"}
{"text": "Second , the severity of thromboembolic and bleeding events may not be judged as similar .Therefore , we weighed all outcome events as serious , life threatening , or fatal and separately analyzed the most severe events only .", "label": "", "metadata": {}, "score": "50.86792"}
{"text": "Results 2183 ( 41.9 % ) patients had coronary angiography during their initial hospital admission , 1065 ( 20.4 % ) had percutaneous coronary intervention , and 208 ( 4.0 % ) had coronary artery bypass surgery .", "label": "", "metadata": {}, "score": "50.93393"}
{"text": "These findings are consistent with registry data and post hoc analyses from clinical trials showing an up to twofold higher event rate compared with patients who have revascularisation .", "label": "", "metadata": {}, "score": "50.94826"}
{"text": "A wide range of demographic , concurrent baseline medications , and other treatment differences were examined for their influence on outcome .Some of these are shown in Figure 9 .", "label": "", "metadata": {}, "score": "50.970924"}
{"text": "SKJ is the guarantor .Funding :This work was supported by AstraZeneca , who funded the PLATO trial .Representatives of the sponsor were involved in study design ; data gathering , analysis , and interpretation ; and revision of the report .", "label": "", "metadata": {}, "score": "51.04602"}
{"text": "The following data were retrieved from these records : indication for anticoagulant therapy , date of birth , sex , duration of treatment , all INR measurements with the corresponding date , hospital admissions , and death .", "label": "", "metadata": {}, "score": "51.2137"}
{"text": "A small number of patients with a history of stroke were included .Based on information external to PEGASUS , 102 patients with a history of stroke ( 90 of whom received study drug ) were terminated early and no further such patients were enrolled .", "label": "", "metadata": {}, "score": "51.23522"}
{"text": "Nine of the 34 nonfatal hemorrhages were life threatening ( 2 intracranial , 7 extracranial ) , as were 4 of the 7 nonfatal thromboembolic events ( 2 ischemic strokes , 2 myocardial infarctions ) .", "label": "", "metadata": {}, "score": "51.477222"}
{"text": "Patients requiring or who were expected to require renal dialysis during the study were excluded .Patients with any previous intracranial hemorrhage , gastrointestinal bleeding within the past 6 months , or with known bleeding diathesis or coagulation disorder were excluded .", "label": "", "metadata": {}, "score": "51.836945"}
{"text": "Outcomes were allocated according to the intention to treat principle .Only outcomes occurring during the time period that patients received study drugs , placebo , or observation were included within the analyses .", "label": "", "metadata": {}, "score": "52.03039"}
{"text": "In addition , we calculated INR - specific incidence rates exclusively for the most severe untoward events ( life threatening or fatal ) .As shown in Table 3 , the anticoagulant intensity that provided the lowest incidence rate of untoward events remained the same .", "label": "", "metadata": {}, "score": "52.054268"}
{"text": "Results Of 157 studies in the literature searches , six were eligible ( 10 117 participants ) .Evidence relating to harms was inconsistent .Conclusions A clear benefit of aspirin in the primary prevention of major cardiovascular events in people with diabetes remains unproved .", "label": "", "metadata": {}, "score": "52.151215"}
{"text": "One might argue , therefore , that although the study results apply to the group as a whole , individual patients may have different risks at different intensities .", "label": "", "metadata": {}, "score": "52.22684"}
{"text": "The data presented herein suggest the following target levels for oral anticoagulation in the prevention of arterial ( thrombo)embolism : an INR of 3.0 for patients with mechanical heart valve prostheses , 3.0 for patients with atrial fibrillation , and 3.5 for patients after myocardial infarction .", "label": "", "metadata": {}, "score": "52.24527"}
{"text": "Patients with previous intracranial hemorrhage , gastrointestinal bleeding within the past 6 months , or with known bleeding diathesis or coagulation disorder were excluded .Patients taking anticoagulants were excluded from participating and patients who developed an indication for anticoagulation during the trial were discontinued from study drug .", "label": "", "metadata": {}, "score": "52.24549"}
{"text": "For the current study , the results of 1,014 patients with diabetes were analyzed ( Supplementary Fig . 1 ) .These patients were randomly assigned to daily consumption of four different trial margarines for a period of 40 months .", "label": "", "metadata": {}, "score": "52.304554"}
{"text": "We selected admissions for 2004 in order to obtain a complete overview of the patient information , including a 1-year period after discharge or death of the patient [ 17 ] .", "label": "", "metadata": {}, "score": "52.309605"}
{"text": "Higher intensities led to incidence rates of 3.6 events per 100 patient - years ( 95 % CI , 2.1 - 5.6 ) for INRs of 4.0 to 4.4 , up to 40.3 per 100 patient - years ( 95 % CI , 27.8 - 55.0 ) for INRs of 5 or greater .", "label": "", "metadata": {}, "score": "52.339653"}
{"text": "Number of Participants With Recurrent Symptomatic Venous Thromboembolism ( VTE ) and Deaths Related to VTE [ Time Frame : For statistical analysis 1 : from randomisation to end of post treatment period ( ptp ) , planned to be up to day 224 .", "label": "", "metadata": {}, "score": "52.60517"}
{"text": "Heterogeneity between studies was assessed with the Cochran 's Q and the I 2 statistics .15 A random effects meta - analysis 16 was used to estimate overall relative risks .", "label": "", "metadata": {}, "score": "52.633423"}
{"text": "Despite the large patient groups and substantial follow - up period of 3 years , the absolute number of untoward events remains relatively small .Although clear patterns are shown , the statistical precision of the outcomes is therefore limited .", "label": "", "metadata": {}, "score": "52.708652"}
{"text": "10 Follow - up of the cases stopped when the event of interest occurred .The 95 % confidence intervals ( CIs ) of the incidence rates were obtained by standard calculations , presuming a Poisson distribution of the number of events .", "label": "", "metadata": {}, "score": "52.70935"}
{"text": "Due to budget constraints , the remainder of the cohort filled out mailed questionnaires only .Outcome .All patients were followed for clinical events , including those who discontinued margarine use during the trial .", "label": "", "metadata": {}, "score": "52.755737"}
{"text": "The incidence of nonfatal thromboembolic events was 1.2 events per 100 patient - years ( 95 % CI , 0.8 - 1.5 ) .Seventeen of the 83 nonfatal hemorrhages were life threatening vs 13 of the 40 nonfatal thromboembolic events .", "label": "", "metadata": {}, "score": "52.911892"}
{"text": "Analyses were carried out according to the intention - to - treat principle .Time - to - event data were analyzed with the Kaplan - Meier method and the log - rank test .", "label": "", "metadata": {}, "score": "53.02978"}
{"text": "All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .Percentage of Participants With Symptomatic Recurrent PE During Observational Period [ Time Frame : 30 days observational period after last intake of study medication ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.13407"}
{"text": "For all the comparisons of incidence rates , consequences and causes , tests for the comparison of proportions in two independent groups were used , corrected for binomial distribution [ 24 ] .", "label": "", "metadata": {}, "score": "53.31372"}
{"text": "Many of these are shown in Figure 8 .Such analyses must be interpreted cautiously , as differences can reflect the play of chance among a large number of analyses .", "label": "", "metadata": {}, "score": "53.369858"}
{"text": "The results were similar for drug - eluting and bare metal stents .The Kaplan - Meier curve ( Figure 7 ) shows time to first occurrence of the primary composite endpoint of CV death , non - fatal MI or non - fatal stroke in the overall study .", "label": "", "metadata": {}, "score": "53.398323"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : Yes ] .All events adjudicated / confirmed by CIAC blinded to treatment .", "label": "", "metadata": {}, "score": "53.52809"}
{"text": "All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee , and all analyses are based on the events that were centrally confirmed by this committee .", "label": "", "metadata": {}, "score": "53.544018"}
{"text": "All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee , and all analyses are based on the events that were centrally confirmed by this committee .", "label": "", "metadata": {}, "score": "53.544018"}
{"text": "All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee , and all analyses are based on the events that were centrally confirmed by this committee .", "label": "", "metadata": {}, "score": "53.544018"}
{"text": "All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee , and all analyses are based on the events that were centrally confirmed by this committee .", "label": "", "metadata": {}, "score": "53.544018"}
{"text": "All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment .For definition of DVT / PE , kindly refer to the link in the Protocol section .", "label": "", "metadata": {}, "score": "53.55727"}
{"text": "In addition , the individual components of the net clinical benefit ( recurrent VTE and major bleeding events ) might not carry the same case fatality rate .", "label": "", "metadata": {}, "score": "53.575874"}
{"text": "During the 3 years of follow - up , 122 946 INR measurements were performed at the anticoagulation clinic in the 4202 participating patients .The mean interval between 2 measurements was 3 weeks .", "label": "", "metadata": {}, "score": "53.6604"}
{"text": "The incidence of nonfatal hemorrhages was 2.4 events per 100 patient - years ( 95 % CI , 1.9 - 2.9 ) .Forty - nine patients experienced a thromboembolic event ( 1.4 events per 100 patient - years ; 95 % CI , 1.0 - 1.9 ) .", "label": "", "metadata": {}, "score": "53.6817"}
{"text": "What is already known on this topic .Ticagrelor reduced ischaemic events and mortality compared with clopidogrel , with similar major bleeding rates , through 12 months in the PLATO trial .", "label": "", "metadata": {}, "score": "53.849617"}
{"text": "This illustrates the increase in statin treatment over 10 years .One of the secondary end points in the Alpha Omega Trial was ventricular arrhythmia - related events .", "label": "", "metadata": {}, "score": "53.86708"}
{"text": "The trials were published between 1989 and 2008 , carried out in several countries , and enrolled from 2.4 % 17 to 100 % of participants with diabetes .", "label": "", "metadata": {}, "score": "53.97704"}
{"text": "If the INR was not measured on hospital admission or if the test result could not be retrieved , we used the last INR measurement at the anticoagulation clinic if the test had been performed within 8 days before the event .", "label": "", "metadata": {}, "score": "53.999634"}
{"text": "Discussion .This systematic review and network meta - analysis determined the rates of recurrent VTE and major bleeding associated with use of antiplatelet agents and oral anticoagulants for the long term secondary prevention of VTE .", "label": "", "metadata": {}, "score": "54.030254"}
{"text": "In the original trial protocol , the primary end point was fatal CHD , and one of the secondary end points was sudden death , a proxy for fatal arrhythmias ( 6 ) .", "label": "", "metadata": {}, "score": "54.06905"}
{"text": "The trial was conducted in accordance with the Helsinki Declaration and approved by one central medical ethics committee and by the committees of all participating hospitals .", "label": "", "metadata": {}, "score": "54.159187"}
{"text": "Antithrombotic Trialists ' Collaboration .Collaborative meta - analysis of randomised trials of antiplatelet therapy for prevention of death , myocardial infarction , and stroke in high risk patients .", "label": "", "metadata": {}, "score": "54.169113"}
{"text": "The interventions are focused both on technical and non - technical aspects of surgical care .Several interventions are incorporated into national safety campaigns , such as infection prevention , reporting and learning from safety incidents , medical team training and the surgical safety checklist [ 15 , 51 , 52 ] .", "label": "", "metadata": {}, "score": "54.419025"}
{"text": "Clinical Studies .Patients were treated for at least 6 months and for up to 12 months .Study endpoints were obtained until the study was complete , even if drug was discontinued .", "label": "", "metadata": {}, "score": "54.434708"}
{"text": "Discussion .This substudy of the PLATO trial indicates that treatment with ticagrelor compared with clopidogrel reduces major ischaemic events without significantly increasing major bleeding across the spectrum of management strategies for acute coronary syndrome .", "label": "", "metadata": {}, "score": "54.444023"}
{"text": "; Alpha Omega Trial Group .Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post - myocardial infarction patients : design and baseline characteristics of the Alpha Omega Trial .", "label": "", "metadata": {}, "score": "54.56239"}
{"text": "Sensitivity analysis excluding ximelagatran from the analysis did not change the results reported ( web appendix 8) .Major bleeding episodes .The analysis on major bleeding episodes included 12 167 patients .", "label": "", "metadata": {}, "score": "54.582542"}
{"text": "RESEARCH DESIGN AND METHODS A subgroup of 1,014 post - MI patients with diabetes aged 60 - 80 years was randomly allocated to receive one of four trial margarines , three with an additional amount of n-3 fatty acids and one placebo for 40 months .", "label": "", "metadata": {}, "score": "54.665695"}
{"text": "Two authors independently reviewed results of the search strategies and identified eligible trials ; data extraction was done independently by the same authors using a predefined form .", "label": "", "metadata": {}, "score": "54.775917"}
{"text": "It was located at an INR of 2.5 to 2.9 for patients with mechanical heart valve prostheses , at an INR of 3.0 to 3.4 for patients with atrial fibrillation , and at an INR of 3.5 to 3.9 for patients treated after a myocardial infarction .", "label": "", "metadata": {}, "score": "54.836155"}
{"text": "In patients with a mechanical heart valve prosthesis , the incidence rate of all major outcome events combined was 4.3 ( 95 % CI , 3.1 - 5.6 ) per 100 patient - years .", "label": "", "metadata": {}, "score": "55.07908"}
{"text": "Events were assessed based on either spiral computed tomography ( CT ) scanning , pulmonary angiography , ventilation / perfusion lung scan , lung scintigraphy , results / films / images of confirmatory testing , and/or case summaries .", "label": "", "metadata": {}, "score": "55.09443"}
{"text": "The incidence of nonfatal hemorrhage was 1.5 events per 100 patient - years ( 95 % CI , 1.1 - 2.0 ) .Sixty thromboembolic events occurred ( 1.9 per 100 patient - years ; 95 % CI , 1.5 - 2.4 ) .", "label": "", "metadata": {}, "score": "55.16944"}
{"text": "Conclusions In patients with acute coronary syndrome initially intended for non - invasive management , the benefits of ticagrelor over clopidogrel were consistent with those from the overall PLATO results , indicating the broad benefits of P2Y12 inhibition with ticagrelor regardless of intended management strategy .", "label": "", "metadata": {}, "score": "55.193398"}
{"text": "A total of 344 person - years ( 4.4 % of the total follow - up time ) were not allocated to an INR interval because the duration between 2 measurements exceeded 8 weeks .", "label": "", "metadata": {}, "score": "55.231537"}
{"text": "The incidence rate of all untoward events was similar for all 3 indications , around 4 % per year .To date , these numbers have been stable .", "label": "", "metadata": {}, "score": "55.251125"}
{"text": "Dyspnea led to study drug discontinuation in 0.9 % of Ticagrelor and 0.1 % of Clopidogrel patients .Common Adverse Events .A variety of non - hemorrhagic adverse events occurred in PLATO at rates of 3 % or more .", "label": "", "metadata": {}, "score": "55.327812"}
{"text": "The same strategy was used for ALA .This was done because in the analysis of the primary end - point major cardiovascular events , the cumulative incidence of the four treatment groups did not differ .", "label": "", "metadata": {}, "score": "55.342674"}
{"text": "If the two surgeons could not reach a consensus , a third surgeon reviewer with access to all the information determined the final judgment .If an AE was identified , the consequences , most responsible specialty , causes and potential prevention strategies were assessed .", "label": "", "metadata": {}, "score": "55.516453"}
{"text": "Strong evidence of preventability .( Virtually ) certain evidence of preventability .Adverse events with a preventability score of 4 to 6 were defined as preventable .", "label": "", "metadata": {}, "score": "55.58722"}
{"text": "We therefore designed a large study among patients using oral anticoagulants because they had mechanical heart valve prostheses , atrial fibrillation , or had experienced a myocardial infarction .", "label": "", "metadata": {}, "score": "55.60735"}
{"text": "Patients with a transient and reversible risk factor for VTE ( that is , a cast , surgery , immobilisation , or recent trauma ) have a low annual risk of recurrent VTE after three months of oral anticoagulation and can safely discontinue anticoagulant treatment .", "label": "", "metadata": {}, "score": "55.622066"}
{"text": "Most patients evaluated in these trials had unprovoked VTE as the indication for continuing anticoagulation or continuing to receive placebo or undergo observation .The trials WODIT PE , 40 EINSTEIN - EXT , 16 and AMPLIFY - EXT 19 included 57 % , 74 % , and more than 90 % of patients with unprovoked events , respectively .", "label": "", "metadata": {}, "score": "55.6311"}
{"text": "Any deaths which occured from randomisation to end of post treatment period .All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee , and all analyses are based on the events that were centrally confirmed by this committee .", "label": "", "metadata": {}, "score": "55.741615"}
{"text": "The most important outcome of secondary prevention studies is the effect on fatal recurrent VTE and fatal bleeding events .The number of fatal events reported in the included studies was infrequent ( table 1 , web appendix 10 ) , leading to imprecise pooled point estimates with large 95 % credible intervals .", "label": "", "metadata": {}, "score": "55.80407"}
{"text": "Table 1 presents the main patient characteristics according to the indication for anticoagulant treatment .In the follow - up period , 1774 patients were admitted to hospital ( 3226 admissions in total ) .", "label": "", "metadata": {}, "score": "55.829136"}
{"text": "Ten studies were designed as double blind , randomised controlled trials .16 17 18 19 20 36 38 39 41 Three studies had an open label design , 35 37 40 of which two had independent , blinded outcome assessment but unclear allocation concealment .", "label": "", "metadata": {}, "score": "55.83838"}
{"text": "Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure ( the GISSI - HF trial ) : a randomised , double - blind , placebo - controlled trial .", "label": "", "metadata": {}, "score": "55.91734"}
{"text": "The PLATO protocol left the choice of aspirin maintenance dose up to the investigator and use patterns were different in US sites from sites outside of the US .", "label": "", "metadata": {}, "score": "55.959183"}
{"text": "Cite this as : BMJ 2013;347:f5133 .Footnotes .Contributors : LAC and CC contributed equally to this study .LAC conceived the study , performed the systematic review , data extraction , analysed the data , and drafted the manuscript .", "label": "", "metadata": {}, "score": "56.007206"}
{"text": "Not all interventions we suggested are evidence - based or evaluated for surgical care .Future research should evaluate the cost - effectiveness of the interventions , especially for surgical specialties .", "label": "", "metadata": {}, "score": "56.082127"}
{"text": "Iorio A , Kearon C , Filippucci E , Marcucci M , Macura A , Pengo V , et al .Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor : a systematic review .", "label": "", "metadata": {}, "score": "56.160667"}
{"text": "Because it depends on the completeness of the information that is recorded in the patient record , the amount of surgical AEs identified in this study could be underestimated .", "label": "", "metadata": {}, "score": "56.192116"}
{"text": "Pharmacogenetics .Clinical Studies .Acute Coronary Syndromes And Secondary Prevention After Myocardial Infarction .PLATO .The study 's primary endpoint was the composite of first occurrence of cardiovascular death , non - fatal MI ( excluding silent MI ) , or non - fatal stroke .", "label": "", "metadata": {}, "score": "56.27822"}
{"text": "Patients who had already been treated with clopidogrel could be enrolled and randomized to either study treatment .Patients could be included whether there was intent to manage the ACS medically or invasively , but patient randomization was not stratified by this intent .", "label": "", "metadata": {}, "score": "56.31249"}
{"text": "Ridker PM , Cook NR , Lee IM , Gordon D , Gaziano JM , Manson JE , et al .A randomized trial of low - dose aspirin in the primary prevention of cardiovascular disease in women .", "label": "", "metadata": {}, "score": "56.443916"}
{"text": "We also could not include some data of trials that enrolled people with diabetes where separate results for this subgroup were not available .19 20 Data extraction , data analysis , and quality assessments of the methods were done by two independent investigators , and consistency was checked with an arbitrator .", "label": "", "metadata": {}, "score": "56.444603"}
{"text": "The benefits of intensified P2Y12 inhibition apply across different management strategies .Notes .Cite this as : BMJ 2011;342:d3527 .Footnotes .Contributors : SKJ participated in study design ; data gathering , analysis , and interpretation ; writing the first draft ; and all revisions of the report .", "label": "", "metadata": {}, "score": "56.495667"}
{"text": "We found the optimal intensity of oral anticoagulant treatment in patients with atrial fibrillation to be an INR of 3.0 to 3.4 ( Figure ) .", "label": "", "metadata": {}, "score": "56.557903"}
{"text": "We calculated the probability that each drug was the most efficacious regimen by counting the proportion of iterations of the Markov chain in which each drug had the highest odds ratio .", "label": "", "metadata": {}, "score": "56.629456"}
{"text": "GLG , EG , PSW , MAR , DC , TC , and GW analysed the data and reviewed the manuscript for important intellectual content .", "label": "", "metadata": {}, "score": "56.68206"}
{"text": "The panel consisted of specialists from all medical disciplines involved in the study .The nurses and medical specialists followed a one - day training course in small groups comprising a maximum of 12 participants led by one researcher and one experienced nurse or medical specialist , respectively .", "label": "", "metadata": {}, "score": "56.726753"}
{"text": "Values are Kaplan - Meier estimates of percentage rate of end point ( numbers ) at 12 months .Fig 3 Cumulative incidence of primary composite of cardiovascular death , myocardial infarction ( MI ) , and stroke in ticagrelor and clopidogrel groups in patients intended for invasive and non - invasive management at time of randomisation .", "label": "", "metadata": {}, "score": "56.73236"}
{"text": "Our study confirms previous data indicating that anticoagulants are effective in reducing the rate of recurrent VTE among patients with previous events .It also provides reliable estimates on consequent risks of major bleeding , which individual studies often could not estimate , given the limited sample size .", "label": "", "metadata": {}, "score": "56.84228"}
{"text": "Table 7 .A selection of well - known interventions to reduce surgical adverse events tailored to the selected prevention strategies in this study .Localizing specific surgical procedures and surgeries to high - volume centers [ 32 , 33 , 38 ] .", "label": "", "metadata": {}, "score": "56.973724"}
{"text": "Steel K , Gertman PM , Crescenzi C , Anderson J : Iatrogenic illness on a general medical service at a university hospital .New England Journal of Medicine .", "label": "", "metadata": {}, "score": "56.998573"}
{"text": "Most of the characteristics shown are baseline characteristics , but some reflect post - randomization determinations ( e.g. , final diagnosis , aspirin maintenance dose , use of PCI ) .", "label": "", "metadata": {}, "score": "57.12077"}
{"text": "Similar effects were observed for the combined end - point cardiac arrest and sudden death ( 0.13 ; CI 0.02 - 1.09 ) and for placement of cardioverter defibrillators ( 0.19 : 0.02 - 1.55 ) .", "label": "", "metadata": {}, "score": "57.137337"}
{"text": "OMEGA , a randomized , placebo - controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline - adjusted therapy after myocardial infarction .", "label": "", "metadata": {}, "score": "57.147118"}
{"text": "Recent meta - analyses quantified the effect of EPA - DHA supplementation on sudden death at a 19 % ( HR 0.81 ; 95 % CI 0.52 - 1.25 ) ( 2 ) and 13 % ( 0.87 ; 0.76 - 0.99 ) reduction ( 3 ) .", "label": "", "metadata": {}, "score": "57.158047"}
{"text": "McCannon CJ , Schall MW , Calkins DR , Nazem AG : Saving 100,000 lives in US hospitals .BMJ .10.1136/bmj.332.7553.1328 .PubMed Central View Article PubMed .", "label": "", "metadata": {}, "score": "57.305626"}
{"text": "When relevant , we also gathered results of laboratory tests , radiographs , computed tomographic ( CT ) scans , and autopsy reports .In this way , all thromboembolic and bleeding events that required hospital admission were registered .", "label": "", "metadata": {}, "score": "57.325813"}
{"text": "The Early Treatment Diabetic Retinopathy Study ( ETDRS ) , the largest study included in our meta - analysis , involved a small proportion of people with previous cardiovascular events , which could not be extrapolated and excluded from the primary analysis .", "label": "", "metadata": {}, "score": "57.592606"}
{"text": "Setting and participants .At the time of randomisation , the treating physician designated patients as planned for initial invasive management or initial conservative management in the interactive voice randomisation system .", "label": "", "metadata": {}, "score": "57.812115"}
{"text": "This difference is largely due to an increased risk of macrovascular diseases among diabetic patients .In addition , they have an increased risk of fatal CHD ( 12 ) and an increased risk of sudden death ( 13 , 14 ) .", "label": "", "metadata": {}, "score": "57.86734"}
{"text": "Setting 862 centres in 43 countries .Participants 5216 ( 28 % ) of 18 624 patients admitted to hospital for acute coronary syndrome who were specified as planned for non - invasive management .", "label": "", "metadata": {}, "score": "57.893867"}
{"text": "To determine whether the injury was caused by health care management or the disease process a 6-point scale was used : .Management causation more likely ( more than 50/50 , but ' close call ' ) .", "label": "", "metadata": {}, "score": "58.06472"}
{"text": "The primary efficacy end point was the composite of death from vascular causes , myocardial infarction , or stroke .Death from vascular causes included cardiovascular deaths , cerebrovascular deaths , or any other death for which no non - vascular cause was clearly documented .", "label": "", "metadata": {}, "score": "58.072613"}
{"text": "The analysis was a pre - specified stratum of the total trial .We used univariable Cox proportional hazards models to analyse the primary and secondary end point results .", "label": "", "metadata": {}, "score": "58.10948"}
{"text": "J Thromb Haemost 2008 ; 6 : 1105 -12 .Carrier M , Le Gal G , Wells PS , Rodger MA .Systematic review : case - fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism .", "label": "", "metadata": {}, "score": "58.177696"}
{"text": "A possible explanation for some of our findings may be the lack of adequate power in existing trials to detect effects of aspirin , either because the efficacy of aspirin was moderate to low in itself or because diabetic status was an effect modifier .", "label": "", "metadata": {}, "score": "58.252262"}
{"text": "It is highly uncertain if such studies will ever be performed .Yet , the study design has major advantages as well .The important features are that we used actually achieved INR levels to calculate the optimal target intensities irrespective of the targets used .", "label": "", "metadata": {}, "score": "58.395786"}
{"text": "Percentage of Participants With Net Clinical Benefit as Composite of Recurrent DVT or Non - fatal or Fatal PE and Major Bleeding Events During Observational Period [ Time Frame : 30 days observational period after last intake of study medication ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.428574"}
{"text": "Some surgical AEs were a result of medical procedures ( 5.5 % ) , for instance urinary tract infection by bladder catheterization and lung bleeding after insertion of a Swann Ganz catheter .", "label": "", "metadata": {}, "score": "58.638924"}
{"text": "Percentage of Participants With Recurrent DVT During Observational Period [ Time Frame : 30 days observational period after last intake of study medication ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.696293"}
{"text": "Summary of network meta - analysis of recurrent VTE and major bleeding episodes .Fig 2 Odds ratio ( 95 % credible interval ) for recurrent VTE and major bleeding episodes in Bayesian network meta - analysis versus placebo or observation .", "label": "", "metadata": {}, "score": "58.797737"}
{"text": "Percentage of Participants With Death ( PE Can not be Excluded ) Until the Intended End of Study Treatment [ Time Frame :6- or 12-month study treatment period ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.79966"}
{"text": "PLATO patients were predominantly male ( 72 % ) and Caucasian ( 92 % ) .Median exposure to study drug was 277 days .About half of the patients received pre - study clopidogrel and about 99 % of the patients received aspirin at some time during PLATO .", "label": "", "metadata": {}, "score": "58.810696"}
{"text": "This patient population has been under - represented in most clinical trials , and no other oral platelet inhibitor has been prospectively investigated in the setting of a primary non - invasive management strategy .", "label": "", "metadata": {}, "score": "58.89324"}
{"text": "Data extraction and quality assessment .Two reviewers ( LAC , MC ) independently assessed eligibility of articles identified in the initial search strategy for inclusion in the review .", "label": "", "metadata": {}, "score": "58.93534"}
{"text": "The national target INR ranges at the start of our study were 3.6 to 4.8 ( for patients with a mechanical heart valve prosthesis ) and 3.0 to 4.5 ( for patients who had experienced a myocardial infarction and for atrial fibrillation ) .", "label": "", "metadata": {}, "score": "59.00851"}
{"text": "Peripheral thromboembolism was diagnosed as sudden peripheral ischemia , proven by duplex scanning , angiography , surgery , or autopsy .To weigh the severity of different untoward events , we adjudicated all outcome events as serious , life threatening , or fatal .", "label": "", "metadata": {}, "score": "59.051468"}
{"text": "This is supported by the recently published results of the OMEGA trial in which patients were randomized 3 - 14 days after acute MI .In these high - risk patients , a supplement of 0.8 g EPA - DHA per day did not reduce sudden cardiac death ( 19 ) .", "label": "", "metadata": {}, "score": "59.052017"}
{"text": "An approach that combines a record review with prospective methods in which clinical staff are interviewed about the origin of the AEs will give a more appropriate and complete picture of the organizational and technical causes .", "label": "", "metadata": {}, "score": "59.113773"}
{"text": "Studies were excluded if patients were risk stratified at the end of the initial anticoagulation period , and if studies included asymptomatic VTE .Outcome measures .", "label": "", "metadata": {}, "score": "59.12973"}
{"text": "However , the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events ( CURE ) trial showed consistent benefit whether or not revascularisation was actually done .", "label": "", "metadata": {}, "score": "59.133953"}
{"text": "Two physician reviewers from the specialty indicated reviewed each record independently and determined whether an AE had occurred .Records with screening criteria concerning surgical care were reviewed by two surgeons .", "label": "", "metadata": {}, "score": "59.209923"}
{"text": "Subgroup analyses , performed to account for heterogeneity due to study duration , yielded results that were more favourable for ASA than those obtained from the primary analysis ( web appendix 7 ) .", "label": "", "metadata": {}, "score": "59.298653"}
{"text": "We found a significantly higher incidence of PLATO defined other major bleedings and of the composite of major and minor bleedings in the ticagrelor group owing to a higher incidence of bleedings related to non - coronary artery bypass grafting during long term treatment .", "label": "", "metadata": {}, "score": "59.310722"}
{"text": "Fatal bleeding .Symptomatic bleeding in a critical area or organ .Bleeding causing a fall in haemoglobin level of 20 g / L ( 1.24 mmol / L ) or more , or leading to transfusion of 2 or more units of whole blood or red cells .", "label": "", "metadata": {}, "score": "59.334076"}
{"text": "Study design and setting .We have performed a patient record review study in a random sample of 21 Dutch hospitals : 4 university , 6 tertiary teaching and 11 general hospitals .", "label": "", "metadata": {}, "score": "59.342926"}
{"text": "We assessed inconsistency by comparing statistics for the deviance and deviance information criterion in fitted consistency and inconsistency models .33 Additionally , the results from our network meta - analysis were qualitatively compared with direct , frequentist , pairwise estimates .", "label": "", "metadata": {}, "score": "59.359253"}
{"text": "1449- 1457 PubMed Link to Article .van Es RFJonker JJVerheugt FWDeckers JWGrobbee DEAntithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 ( ASPECT-2 ) Research Group , Aspirin and coumadin after acute coronary syndromes ( the ASPECT-2 study ) : a randomised controlled trial .", "label": "", "metadata": {}, "score": "59.47123"}
{"text": "Methods .A structured record review study of 7,926 patient records was carried out by trained nurses and medical specialist reviewers in 21 Dutch hospitals .", "label": "", "metadata": {}, "score": "59.6963"}
{"text": "Heit JA , Mohr DN , Silverstein MD , Petterson TM , O'Fallon WM , Melton LJ 3rd .Predictors of recurrence after deep vein thrombosis and pulmonary embolism : a population - based cohort study .", "label": "", "metadata": {}, "score": "59.69712"}
{"text": "E.B. was the chair of the Data Safety and Monitoring Board of the Alpha Omega Trial .E.J.G. designed the study , performed statistical analysis , and collected data .", "label": "", "metadata": {}, "score": "59.7161"}
{"text": "At the final examination , the effect of n-3 fatty acid supplementation on fatty acids in serum cholesteryl esters was compared with placebo ( Supplementary Fig . 2 ) .", "label": "", "metadata": {}, "score": "59.72139"}
{"text": "RESEARCH DESIGN AND METHODS .Design and patients .The Alpha Omega Trial is a multicenter , double - blind , placebo - controlled trial with a 2 \u00d7 2 factorial design , which has been described in detail elsewhere ( 6 , 7 ) .", "label": "", "metadata": {}, "score": "59.727882"}
{"text": "Table 4 shows the study results for the primary composite endpoint and the contribution of each component to the primary endpoint .Separate secondary endpoint analyses are shown for the overall occurrence of CV death , MI , and stroke and overall mortality .", "label": "", "metadata": {}, "score": "59.768536"}
{"text": "Outcomes .The rate of myocardial infarction and the composite of cardiovascular death and other thromboembolic events did not differ significantly between the groups .Table 3 .", "label": "", "metadata": {}, "score": "59.772667"}
{"text": "Return to : Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses , Atrial Fibrillation , or Myocardial Infarction : A Prospective Study of 4202 Patients .", "label": "", "metadata": {}, "score": "59.805622"}
{"text": "A strong aspect of the study is the large number of patient records that were reviewed systematically .The use of a random , stratified , sample of diverse patient admissions and a systematic screening process led to results representative of Dutch hospitals .", "label": "", "metadata": {}, "score": "59.880997"}
{"text": "Most of the characteristics shown are baseline characteristics , but some reflect post - randomization determinations ( e.g. , aspirin maintenance dose , use of PCI ) .", "label": "", "metadata": {}, "score": "59.908188"}
{"text": "Antithrombotic Trialists ' ( ATT ) Collaboration , Baigent C , Blackwell L , Collins R , Emberson J , Godwin J , et al .", "label": "", "metadata": {}, "score": "59.943077"}
{"text": "Finally , for all preventable AEs , potential prevention strategies were selected .The categories were based on PRISMA and the Canadian patient record review study [ 1 , 22 ] .", "label": "", "metadata": {}, "score": "60.04055"}
{"text": "J.M.G. obtained an unrestricted grant from the Alpro Foundation ( Belgium ) for epidemiologic analyses within a project on ALA , CHD , and stroke in the general population .", "label": "", "metadata": {}, "score": "60.08638"}
{"text": "Events were assessed based on either compression ultrasound or venography , results / films / images of confirmatory testing , and/or case summaries .Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once - daily .", "label": "", "metadata": {}, "score": "60.129368"}
{"text": "We also searched the Cochrane central register of controlled trials ( Cochrane Library 2008;issue 4 ) for studies meeting these criteria .14 Searches were limited to published English language articles .", "label": "", "metadata": {}, "score": "60.13878"}
{"text": "Table 5 shows results by region and dose .Table 5 - PLATO : CV Death , MI , Stroke by maintenance aspirin dose in the US and outside the US .", "label": "", "metadata": {}, "score": "60.359528"}
{"text": "Procedures .For logistical reasons , all patients used placebo margarine during the first 4 - 6 weeks after randomization , after which actual treatment started .", "label": "", "metadata": {}, "score": "60.38378"}
{"text": "J.M.G. designed the study and collected data .J.d .G. and L.M.O.G. collected data .B.J.M.M. was the chair .M.-J.d .B. and P.L.Z. were observers of the Steering Committee .", "label": "", "metadata": {}, "score": "60.3888"}
{"text": "We used adjusted continuity corrections of 0.5 to account for studies with no events .25 The absolute risk difference per 100 patients treated each year for each outcome was also calculated , 26 27 based on median rates of all placebo arms for both recurrent VTE ( 10.1 per 100 patient years ) and major bleeding ( 0.3 ) .", "label": "", "metadata": {}, "score": "60.4498"}
{"text": "In the Alpha Omega Trial , an even stronger reduction of 61 % of ventricular arrhythmia - related events was observed for ALA .This evokes the question of whether post - MI patients with diabetes are particularly susceptible to protective effects of n-3 fatty acids on fatal CHD and ventricular arrhythmia - related events .", "label": "", "metadata": {}, "score": "60.469955"}
{"text": "View Article PubMed .Vincent C , Neale G , Woloshynowych M : Adverse events in British hospitals : preliminary retrospective record review .BMJ .", "label": "", "metadata": {}, "score": "60.47014"}
{"text": "Harbison SP , Regehr G : Faculty and Resident Opinions Regarding the Role of Morbidity and Mortality Conference .Am J Surg .10.1016/S0002 - 9610(98)00319 - 5 .", "label": "", "metadata": {}, "score": "60.51439"}
{"text": "no .The results of more trials on the effect of different n-3 fatty acids are needed before definitive conclusions can be drawn on their role in the etiology of ventricular arrhythmias and fatal CHD .", "label": "", "metadata": {}, "score": "60.63882"}
{"text": "FP and GG were involved in data analysis .GS was involved in critical revision for intellectual content and interpretation of data and assisted with writing the final manuscript .", "label": "", "metadata": {}, "score": "60.826126"}
{"text": "25 An effect was evident in all participants enrolled in the Women 's Health Study .Strengths and limitations of the meta - analysis . 7 A strength of this investigation is that it represents a comprehensive review , based on a predefined study protocol and rigid inclusion criteria for randomised trials only , and deriving from a comprehensive search of Medline and the Cochrane central register of controlled trials .", "label": "", "metadata": {}, "score": "60.862995"}
{"text": "Participants who did not complete the treatment period also entered the observational period .It was also possible that participants did not enter the observational period , e.g. due to withdrawal of consent or termination of study participation .", "label": "", "metadata": {}, "score": "60.882294"}
{"text": "The increased risk of hemorrhage remains the major drawback to this therapy and is associated with the intensity of anticoagulation .Finding the optimal intensity at which the overall incidence rate of both bleeding and thromboembolic events is minimized represents a way to improve the safety of oral anticoagulant treatment .", "label": "", "metadata": {}, "score": "60.95298"}
{"text": "PLATO excluded patients at increased risk of bradycardic events ( e.g. , patients who have sick sinus syndrome , 2nd or 3rd degree AV block , or bradycardic - related syncope and not protected with a pacemaker ) .", "label": "", "metadata": {}, "score": "60.969086"}
{"text": "Belch J , MacCuish A , Campbell I , Cobbe S , Taylor R , Prescott R , et al .The prevention of progression of arterial disease and diabetes ( POPADAD ) trial : factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease .", "label": "", "metadata": {}, "score": "61.036304"}
{"text": "Heterogeneity between trials was found in some analyses , which most likely reflects a sex interaction , but other causes of heterogeneity could not be explored owing to the scarcity of data .", "label": "", "metadata": {}, "score": "61.14531"}
{"text": "Although not confirmed in trials of only people with diabetes , several studies in the general population have shown an absolute excess of about one to two major bleeding complications for every 1000 people treated with low doses of aspirin for one year .", "label": "", "metadata": {}, "score": "61.18035"}
{"text": "Preventability was defined as care that fell below the current professional standards and expected performance for practitioners or systems .Consistent with most previous international studies , we used a score of one to three to indicate that AEs were not preventable and a score of at least four to indicate that AEs were preventable [ 18 ] .", "label": "", "metadata": {}, "score": "61.199924"}
{"text": "MZ wrote the manuscript , prepared the protocol and instruments of the study , and collected and analyzed the data .MCB contributed to the manuscript , the design and conception of the study .", "label": "", "metadata": {}, "score": "61.206455"}
{"text": "We also included data on subsets of people with diabetes who were enrolled in larger studies of the general population or patients with a mixed baseline risk for cardiovascular events , where aspirin was tested against placebo or no treatment .", "label": "", "metadata": {}, "score": "61.210243"}
{"text": "Rationale , design , and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia : the ORIGIN Trial ( Outcome Reduction with an Initial Glargine Intervention ) .", "label": "", "metadata": {}, "score": "61.236275"}
{"text": "Fatal recurrent venous thromboembolism and fatal bleeding were rare .Detailed subgroup and individual patient level data were not available .Conclusions All oral anticoagulants and antiplatelet agents investigated in this analysis were associated with a reduced recurrence of venous thromboembolism compared with placebo or observation , although acetylsalicylic acid was associated with the lowest risk reduction .", "label": "", "metadata": {}, "score": "61.2844"}
{"text": "American College of Chest Physicians Evidence - Based Clinical Practice Guidelines .Chest 2012 ; 141 : e419 -94S. .Fox BD , Kahn SR , Langleben D , Eisenberg MJ , Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism : direct and adjusted indirect meta - analysis of randomised controlled trials .", "label": "", "metadata": {}, "score": "61.288696"}
{"text": "Safety .Although rates of PLATO defined overall major bleeding did not differ significantly between the randomised groups , an excess of minor bleedings occurred , particularly of those not related to coronary artery bypass grafting during long term treatment .", "label": "", "metadata": {}, "score": "61.479996"}
{"text": "The number of VTE events and associated morbidity and mortality .Thromb Haemost 2007 ; 98 : 756 -64 .Silverstein MD , Heit JA , Mohr DN , Petterson TM , O'Fallon WM , Melton LJ 3rd .", "label": "", "metadata": {}, "score": "61.50637"}
{"text": "Bassand JP , Hamm CW , Ardissino D , Boersma E , Budaj A , Fernandez - Aviles F , et al .Guidelines for the diagnosis and treatment of non - ST - segment elevation acute coronary syndromes .", "label": "", "metadata": {}, "score": "61.572044"}
{"text": "Review methods Randomised controlled trials of patients receiving anticoagulants , antiplatelet drugs , or placebo or observation for secondary prevention of venous thromboembolism .Selected outcomes were rates of recurrent venous thromboembolism and major bleeding .", "label": "", "metadata": {}, "score": "61.586327"}
{"text": "The estimates of effect derived from the direct , frequentist pairwise comparisons aligned well with those obtained from the network meta - analysis ( web appendix 5 ) .", "label": "", "metadata": {}, "score": "61.692642"}
{"text": "After randomisation , subsequent decisions to do angiography and revascularisation based on changes in the patients ' clinical statuses were not restricted .Randomisation and interventions .", "label": "", "metadata": {}, "score": "61.769455"}
{"text": "Anthropometric measures , blood pressure , and heart rate were taken , and nonfasting blood was collected for determining serum lipids , plasma cholesteryl esters , and glucose ( 6 ) .", "label": "", "metadata": {}, "score": "61.774353"}
{"text": "The width of lines for each connection in the evidence network are proportional to the number of randomised controlled trials ( RCTs ) comparing each pair of treatments .", "label": "", "metadata": {}, "score": "61.95455"}
{"text": "Nor did we find any significant difference between the randomised groups when we used the TIMI definition of major bleeding .The incidence of life threatening or fatal major bleedings did not differ between the groups .", "label": "", "metadata": {}, "score": "62.044952"}
{"text": "Treatment - emergent events ( after intake of 1st study medication tablet as randomized up to 2 days after stop of study medication [ ' time window : 2 days ' ] ) and all events post randomization were reported .", "label": "", "metadata": {}, "score": "62.08037"}
{"text": "A priori subgroup analysis was conducted to adjust for differences in study duration .We also did a priori sensitivity analysis using placebo and observation as separate nodes within the evidence network , to ensure that they could be combined .", "label": "", "metadata": {}, "score": "62.11577"}
{"text": "1186/\u200b1754- 9493 - 5 - 13 ) contains supplementary material , which is available to authorized users .Background .Adverse events are a major source of morbidity and mortality .", "label": "", "metadata": {}, "score": "62.169018"}
{"text": "The data were analyzed according to the intention - to - treat principle , using multivariable Cox proportional hazards models .RESULTS The patients consumed on average 18.6 g of margarine per day , which resulted in an additional intake of 223 mg EPA plus 149 mg DHA and/or 1.9 g ALA in the active treatment groups .", "label": "", "metadata": {}, "score": "62.242096"}
{"text": "Confidence intervals in this analysis argue for a potential benefit of aspirin , compatible with that observed in other high risk populations , but the benefit was small at best or trials were underpowered to detect it with sufficient precision .", "label": "", "metadata": {}, "score": "62.251694"}
{"text": "RESULTS .Baseline characteristics .The definition of diabetes was made in 72.4 % on the combination of elevated blood glucose levels , physician - diagnosed self - report , and drug treatment , in 14.4 % on elevated glucose levels only , in 9.9 % on self - report only , and in 3.4 % on drug treatment only .", "label": "", "metadata": {}, "score": "62.331017"}
{"text": "Data sharing : The authors are willing to share the protocol and the statistical analysis plan for this study but will not be able to share the database .", "label": "", "metadata": {}, "score": "62.40342"}
{"text": "In conclusion , low doses of n-3 fatty acids reduced the risk of ventricular arrhythmia - related events in post - MI patients who also have diabetes .", "label": "", "metadata": {}, "score": "62.40954"}
{"text": "Surgical interventions by their nature are associated with a higher degree of risk .The increasingly complicated techniques and innovations , however , also enhance the potential for error [ 15 , 16 , 26 ] .", "label": "", "metadata": {}, "score": "62.41221"}
{"text": "VTE or any death which occured from randomisation to end of post treatment period .All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee , and all analyses are based on the events that were centrally confirmed by this committee .", "label": "", "metadata": {}, "score": "62.42752"}
{"text": "Surgical techniques have been improved , increasing the opportunities for successful treatment of complex diseases .However , this also increases the potential for errors that can result in patient harm , leading to disability or death [ 15 , 16 ] .", "label": "", "metadata": {}, "score": "62.486225"}
{"text": "The ongoing TRILOGY ( NCT00699998 ) trial is investigating the efficacy and safety of the thienopyridine prasugrel compared with clopidogrel in patients at high risk selected for medical management of acute coronary syndrome .", "label": "", "metadata": {}, "score": "62.512024"}
{"text": "More than half of the AEs attributable to anesthesiology , plastic surgery and orthopedics were judged to be preventable ( Table 3 ) .AEs attributable to vascular surgery ( 23.3 % ) , anesthesiology ( 22.2 % ) , heart / thorax surgery ( 19.2 % ) , and plastic surgery ( 18.2 % ) contributed relatively often to permanent disability including death .", "label": "", "metadata": {}, "score": "62.53195"}
{"text": "Leape LL , Brennan TA , Laird N , Lawthers AG , Localio AR , Barnes BA , Herbert L , Newhouse JP , Weiler PC , Haitt H : The nature of adverse events in hospitalized patients .", "label": "", "metadata": {}, "score": "62.557583"}
{"text": "The rates of recurrent VTE and major bleeding events need to be interpreted in combination with the case fatality rates to allow a better estimate of benefit to harm in the secondary prevention of VTE .", "label": "", "metadata": {}, "score": "62.803368"}
{"text": "The Worcester study .Arch Intern Med 1991 ; 151 : 933 -8 .Kearon C , Akl EA , Comerota AJ , Prandoni P , Bounameaux H , Goldhaber SZ , et al .", "label": "", "metadata": {}, "score": "62.826874"}
{"text": "The following characteristics of the population , intervention , and methodological quality of the trials were defined a priori as potential effect modifiers : sex , dose of aspirin , duration of treatment , allocation concealment , and compliance with treatment .", "label": "", "metadata": {}, "score": "62.900757"}
{"text": "It will be reviewed by JAMA Internal Medicine editors .You will be notified when your comment has been published .Comments should not exceed 500 words of text and 10 references .", "label": "", "metadata": {}, "score": "63.01828"}
{"text": "A patient record review of hospitalized patients is by far the most applied and thoroughly studied method for the assessment of the occurrence and nature of AEs [ 27 ] .", "label": "", "metadata": {}, "score": "63.084473"}
{"text": "In addition , 27 patients died of MI , 23 from other vascular diseases , 34 from cancer , and 26 from other causes .The Kaplan - Meier curves showed that both EPA - DHA and ALA reduced ventricular arrhythmia - related events compared with placebo ( Fig . 1 A ) .", "label": "", "metadata": {}, "score": "63.089905"}
{"text": "The consistency of the differences in both the CV mortality and non - fatal MI components , however , supports the possibility that the finding is reliable .", "label": "", "metadata": {}, "score": "63.198776"}
{"text": "The consistency of the differences in both the CV mortality and non - fatal MI components , however , supports the possibility that the finding is reliable .", "label": "", "metadata": {}, "score": "63.198776"}
{"text": "The results in the subsets based on final diagnosis ( STEMI , NSTEMI and unstable angina ) are also presented in Figure 8 .Results in the rest of the world compared to effects in North America ( US and Canada ) show a smaller effect in North America , numerically inferior to the control and driven by the US subset .", "label": "", "metadata": {}, "score": "63.205025"}
{"text": "Based on current standards , the quality of the included studies was suboptimal .Allocation concealment was adequately described in three of the six studies 9 10 22 and unclear in the remainder . 8 17 21 All the studies adequately described blinding of outcome assessors and five reported an intention to treat analysis . 8 9 10 21 22 Only one study reported funding from industry .", "label": "", "metadata": {}, "score": "63.226334"}
{"text": "Unused margarine tubs were returned .Based on this information , the daily intakes of margarine and n-3 fatty acids were calculated .An objective measure of compliance was obtained by determining fatty acids in plasma cholesteryl esters in random subgroups of patients at baseline and after 20 and 40 months of intervention .", "label": "", "metadata": {}, "score": "63.299873"}
{"text": "Structured review of patient records .The nursing , medical and , if available , outpatient records of the 7,926 sampled hospital admissions were reviewed in a three stage review process .", "label": "", "metadata": {}, "score": "63.438828"}
{"text": "Participation in another clinical trial with an investigational drug during the last 30 days or previous participation in this study .Choosing to participate in a study is an important personal decision .", "label": "", "metadata": {}, "score": "63.441032"}
{"text": "8 9 Patients were included if they were admitted to hospital with ST segment elevation acute coronary syndrome scheduled for primary percutaneous coronary intervention or non - ST segment elevation acute coronary syndrome , with onset of symptoms during the previous 24 hours .", "label": "", "metadata": {}, "score": "63.603703"}
{"text": "A post hoc analysis of the Alpha Omega Trial showed that in post - MI patients with diabetes , EPA - DHA reduced both fatal CHD and ventricular arrhythmia - related events by 49 % ( 7 ) .", "label": "", "metadata": {}, "score": "63.606823"}
{"text": "Conclusion .Taken together our findings contrast with prevailing beliefs and existing summaries of evidence and guidelines based on trials done in populations at higher risk of cardiac events .", "label": "", "metadata": {}, "score": "63.701996"}
{"text": "Evidence synthesis for decision making 4 : inconsistency in networks of evidence based on randomized controlled trials .Med Decis Making 2013 ; 33 : 641 -56 .", "label": "", "metadata": {}, "score": "63.70453"}
{"text": "The clinic annually treats over 6000 patients .In the period of 1994 to 1998 , we included all patients of the Leiden Anticoagulation Clinic who were treated with vitamin K antagonists for mechanical heart valve prostheses , atrial fibrillation , or after a myocardial infarction .", "label": "", "metadata": {}, "score": "63.712685"}
{"text": "Most of the analyses show effects consistent with the overall results , but there are two exceptions : a finding of heterogeneity by region and a strong influence of the maintenance dose of aspirin .", "label": "", "metadata": {}, "score": "63.82749"}
{"text": "In view of the similar rates of patient important outcomes among the various sources of secondary prevention strategies , further evaluation of existing data is needed to determine the most cost effective approach .", "label": "", "metadata": {}, "score": "63.91946"}
{"text": "Figure 2 - Mean inhibition of platelet aggregation ( \u00b1SE ) following single oral doses of placebo , 180 mg ticagrelor or 600 mg clopidogrel .", "label": "", "metadata": {}, "score": "64.01541"}
{"text": "Figure 2 - Mean inhibition of platelet aggregation ( \u00b1SE ) following single oral doses of placebo , 180 mg ticagrelor or 600 mg clopidogrel .", "label": "", "metadata": {}, "score": "64.01541"}
{"text": "Relatively minor effects such as delays in pinna unfolding and eye opening occurred at doses of 10 and 60 mg / kg ( approximately one - half and 3.2 times the MRHD on a mg / m2 basis ) .", "label": "", "metadata": {}, "score": "64.018555"}
{"text": "All patients randomized to BRILINTA received a loading dose of 180 mg followed by a maintenance dose of 90 mg twice daily .Patients in the clopidogrel arm were treated with an initial loading dose of clopidogrel 300 mg , if clopidogrel therapy had not already been given .", "label": "", "metadata": {}, "score": "64.05328"}
{"text": "We did Bayesian network meta - analyses using a binomial likelihood model .23 Network meta - analyses were performed on two different evidence networks .", "label": "", "metadata": {}, "score": "64.05823"}
{"text": "OBJECTIVE We carried out a secondary analysis in high - risk patients with a previous myocardial infarction ( MI ) and diabetes in the Alpha Omega Trial .", "label": "", "metadata": {}, "score": "64.0945"}
{"text": "Data sources and searches .We conducted a systematic literature search strategy to identify potential studies on Medline ( 1950 to present ) , Embase ( 1980 to present ) , and the Cochrane Register of Controlled Trials using the OVID interface .", "label": "", "metadata": {}, "score": "64.119415"}
{"text": "Because these reactions are reported voluntarily from a population of an unknown size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "64.1336"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00439725 Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non - invasive management : substudy from prospective randomised PLATelet inhibition and patient Outcomes ( PLATO ) trial .", "label": "", "metadata": {}, "score": "64.166245"}
{"text": "It should also be noted that other potentially important safety parameters ( such as coronary artery events and hepatotoxicity ) were not evaluated within this review .", "label": "", "metadata": {}, "score": "64.17155"}
{"text": "JM declares research grants from AstraZeneca , Bayer , Daiichi Sankyo , MSD / Schering - Plough , and Eli Lilly .Ethical approval : The trial was approved by ethical review boards .", "label": "", "metadata": {}, "score": "64.298996"}
{"text": "Patients undergoing PCI could receive an additional 300 mg of clopidogrel at investigator discretion .All subjects randomized to Brilinta received a loading dose of 180 mg followed by a maintenance dose of 90 mg twice daily .", "label": "", "metadata": {}, "score": "64.30388"}
{"text": "Dias S , Welton NJ , Sutton AJ , Ades A. NICE DSU technical support document 2 : a generalised linear modelling framework for pairwise and network meta - analysis of randomised controlled trials .", "label": "", "metadata": {}, "score": "64.33411"}
{"text": "AE : .Declarations .Acknowledgements .We would like to thank everyone who contributed to the study : the nurse and specialist reviewers , the researchers for the co - ordination of the data collection , and the 21 hospitals and their staff who participated for facilitating the patient records .", "label": "", "metadata": {}, "score": "64.39576"}
{"text": "All figures in this paper were corrected for the sampling frame and were representative of the Dutch population of hospitalized patients [ 18 ] .The methods were based on previous AE studies in other countries and have been described in detail elsewhere [ 17 ] .", "label": "", "metadata": {}, "score": "64.45969"}
{"text": "Dissatisfaction with care documented in the medical record .Documentation or correspondence indicating litigation .Any other undesirable outcome not covered above .The determination of an adverse event was based on three criteria [ 17 ] : . an unintended ( physical and/or mental ) injury which .", "label": "", "metadata": {}, "score": "64.53235"}
{"text": "Baseline characteristics of post - MI patients with diabetes are presented in Table 1 .Randomization was successful , though small group differences were found for sex and smoking .", "label": "", "metadata": {}, "score": "64.60004"}
{"text": "10.1136/qshc.2005.016220 .View Article PubMed . van Vuuren W , Shea CE , van der Schaaf TW : The development of an incident analysis tool for the medical field .", "label": "", "metadata": {}, "score": "64.69289"}
{"text": "Figure 3 : Mean inhibition of platelet aggregation ( \u00b1SE ) following single oral doses of placebo , 180 mg ticagrelor or 600 mg clopidogrel .", "label": "", "metadata": {}, "score": "64.71432"}
{"text": "leading to hospitalisation and / or requiring surgical treatment . any other bleeding event considered clinically relevant by the investigator .Any bleeding events were defined as major , clinically - relevant and nuisance bleeding events .", "label": "", "metadata": {}, "score": "64.750305"}
{"text": "Web appendix 6 reports detailed estimates for the ASA versus placebo comparison .Compared with low dose VKA , standard adjusted dose VKA reduced the risk of recurrent VTE ( 0.25 ( 0.10 to 0.58 ) ; fig 3 ) .", "label": "", "metadata": {}, "score": "64.752075"}
{"text": "Of all AEs , the consequences , responsible medical specialty , causes and potential prevention strategies were identified .Surgical AEs were defined as AEs attributable to surgical treatment and care processes and were selected for analysis in detail .", "label": "", "metadata": {}, "score": "64.76265"}
{"text": "Ryd\u00e9n L , Standl E , Bartnik M , Van den Berghe G , Betteridge J , de Boer MJ , et al .Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology ( ESC ) ; European Association for the Study of Diabetes ( EASD ) .", "label": "", "metadata": {}, "score": "64.82419"}
{"text": "Data sources Literature search using Medline ( 1950 to present ) , Embase ( 1980 to present ) , and the Cochrane Register of Controlled Trials using the OVID interface .", "label": "", "metadata": {}, "score": "64.825836"}
{"text": "10.1136/qshc.2007.024166 .View Article PubMed .Violato C , Lockyer J , Fidler H : Multisource feedback : a method of assessing surgical practice .", "label": "", "metadata": {}, "score": "64.909706"}
{"text": "All patients received acetylsalicylic acid ( aspirin ) unless they were intolerant of it .The randomised treatment continued for a minimum of six months and a maximum of 12 months ; the median length of study treatment in the overall population was 9.1 months .", "label": "", "metadata": {}, "score": "64.92863"}
{"text": "Figure 10 : CV death , MI , stroke by maintenance aspirin dose in the US and outside the US ( PLATO ) .Like any unplanned subset analysis , especially one where the characteristic is not a true baseline characteristic ( but may be determined by usual investigator practice ) , the above analyses must be treated with caution .", "label": "", "metadata": {}, "score": "64.959335"}
{"text": "Salanti G , Ades AE , Ioannidis JP .Graphical methods and numerical summaries for presenting results from multiple - treatment meta - analysis : an overview and tutorial .", "label": "", "metadata": {}, "score": "64.99844"}
{"text": "Effects of n-3 fatty acids on study end points .The median follow - up period was 40.7 months ( IQR 36.6 - 41.6 months ) , during which 3,195 person - years of follow - up were accumulated .", "label": "", "metadata": {}, "score": "65.01962"}
{"text": "Untoward events were major thromboembolism and major hemorrhage .We calculated intensity - specific incidence rates of untoward events to assess the optimal intensity per indication of treatment .", "label": "", "metadata": {}, "score": "65.03627"}
{"text": "We conducted both treatment and class level analyses to provide the most information to guide clinical decision making .Although ximelagatran is not commercially available , the drug was included in our analysis because it improved the precision of the other estimates .", "label": "", "metadata": {}, "score": "65.04074"}
{"text": "While this clinical experience has not identified differences in responses between the elderly and younger patients , greater sensitivity of some older individuals can not be ruled out .", "label": "", "metadata": {}, "score": "65.0511"}
{"text": "The study did not receive specific funding .MC is a recipient of a New Investigator Award from the Heart and Stroke Foundation of Canada and holds a T2 research chair in cancer and thrombosis from the University of Ottawa .", "label": "", "metadata": {}, "score": "65.082375"}
{"text": "Major cardiovascular events .Fig 2 Effect of aspirin therapy on primary prevention of major cardiovascular events , myocardial infarction , stroke , death from cardiovascular causes , and all cause mortality in participants with diabetes .", "label": "", "metadata": {}, "score": "65.11693"}
{"text": "Data sharing : No additional data available .References .Cohen AT , Agnelli G , Anderson FA , Arcelus JI , Bergqvist D , Brecht JG , et al .", "label": "", "metadata": {}, "score": "65.16632"}
{"text": "The higher incidence of minor bleedings should be taken into consideration in patients at low risk not intended for invasive treatment , as patients at low risk of thromboembolic events have a low potential benefit from more extensive antithrombotic treatment and bleeding complications tend to accrue over time .", "label": "", "metadata": {}, "score": "65.17556"}
{"text": "20 35 39 One trial compared two active treatments and placebo .The sample size ranged from 162 to 2856 people , with a median sample size of 780 .", "label": "", "metadata": {}, "score": "65.18117"}
{"text": "Taken together these data indicate either low efficacy of aspirin in people with diabetes or insufficient evidence .In many analyses there was a significant heterogeneity , explored by subgroup analysis for specific end points ( myocardial infarction and stroke ) based on selective exposures .", "label": "", "metadata": {}, "score": "65.2337"}
{"text": "Methods .We included prospective , randomised , controlled , open or blinded trials of participants with diabetes mellitus who were allocated to aspirin treatment or a control group ( placebo or no treatment ) for the primary prevention of cardiovascular disease .", "label": "", "metadata": {}, "score": "65.259155"}
{"text": "The curves separate by 30 days [ relative risk reduction ( RRR ) 12 % ] and continue to diverge throughout the 12 month treatment period ( RRR 16 % ) .", "label": "", "metadata": {}, "score": "65.28995"}
{"text": "Comparative efficacy and acceptability of 12 new - generation antidepressants : a multiple - treatments meta - analysis .Lancet 2009 ; 373 : 746 -58 .", "label": "", "metadata": {}, "score": "65.32733"}
{"text": "PubMed Central PubMed .Michel P , Quenon JL , Djihoud A , Tricaud - Vialle S , de Sarasqueta AM : French national study of inpatient adverse events prospectively assessed with ward staff .", "label": "", "metadata": {}, "score": "65.32745"}
{"text": "N Engl J Med 2003 ; 349 : 631 -9 .Schulman S , Wahlander K , Lundstrom T , Billing Classon S , Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran .", "label": "", "metadata": {}, "score": "65.333885"}
{"text": "Compared with placebo patients , the EPA - DHA plus ALA group experienced less ventricular arrhythmia - related events ( hazard ratio 0.16 ; 95 % CI 0.04 - 0.69 ) .", "label": "", "metadata": {}, "score": "65.37585"}
{"text": "Notes .Cite this as : BMJ 2009;339:b4531 .Footnotes .Contributors : AN was involved in the concept and design of the review , analysis and interpretation of data , and writing the final manuscript .", "label": "", "metadata": {}, "score": "65.40275"}
{"text": "In a Holter substudy of about 3000 patients in PLATO , more patients had ventricular pauses with Ticagrelor ( 6.0 % ) than with Clopidogrel ( 3.5 % ) in the acute phase ; rates were 2.2 % and 1.6 % respectively after 1 month .", "label": "", "metadata": {}, "score": "65.41937"}
{"text": "The diagnosis of ischemic stroke required an acute neurological deficit confined to the blood supply of a single brain artery and confirmed by CT scan or autopsy .", "label": "", "metadata": {}, "score": "65.44906"}
{"text": "Description of 18 screening criteria for potential adverse events [ 17 ] .Unplanned admission before index admission ( admission reasons are related to the index admission ) .", "label": "", "metadata": {}, "score": "65.54491"}
{"text": "To prevent overlap in these definitions , we limited in the present analysis fatal CHD to death from MI ( I20-I25 ) .Statistical analysis .", "label": "", "metadata": {}, "score": "65.5506"}
{"text": "First , it should be assessed whether the protective effects of oral anticoagulants outweigh the introduced bleeding risk because we would otherwise just exchange one risk for the other .", "label": "", "metadata": {}, "score": "65.5526"}
{"text": "Previous population - based record review studies that reported on AEs attributable to surgical specialties in detail are now more than ten years old [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "65.61391"}
{"text": "Palareti GManotti CD'Angelo A et al .Thrombotic events during oral anticoagulant treatment : results of the inception - cohort , prospective , collaborative ISCOAT study : ISCOAT study group ( Italian Study on Complications of Oral Anticoagulant Therapy ) .", "label": "", "metadata": {}, "score": "65.618355"}
{"text": "Palareti GManotti CD'Angelo A et al .Thrombotic events during oral anticoagulant treatment : results of the inception - cohort , prospective , collaborative ISCOAT study : ISCOAT study group ( Italian Study on Complications of Oral Anticoagulant Therapy ) .", "label": "", "metadata": {}, "score": "65.618355"}
{"text": "Frequency of patients with possible clinically significant abnormalities .Acute deep vein thrombosis ( DVT ) of the leg involving proximal veins , and/or pulmonary embolism ( PE ) iin patients for whom at least 6 months of anticoagulant therapy is considered appropriate .", "label": "", "metadata": {}, "score": "65.68707"}
{"text": "For fatal cases , death certificates were obtained from Statistics Netherlands and general practitioners filled out a standard form on primary and contributing causes of death .", "label": "", "metadata": {}, "score": "65.71695"}
{"text": "Of all surgical AEs , 40.5 % were judged to be preventable .Table 2 presents examples of surgical AEs identified in this study .Pneumonia after thoracotomy , resulting in artificial ventilation and antibiotics .", "label": "", "metadata": {}, "score": "65.719795"}
{"text": "The incidence , preventability , nature , consequences , causes and potential prevention strategies of surgical AEs were analyzed using descriptive statistics and frequency tables .", "label": "", "metadata": {}, "score": "65.76515"}
{"text": "Many events are early , at a time of coronary angiography , PCI , CABG , and other procedures , but the risk persists during later use of antiplatelet therapy .", "label": "", "metadata": {}, "score": "65.820335"}
{"text": "van Swieten JCKoudstaal PJVisser MCSchouten HJvan Gijn J Interobserver agreement for the assessment of handicap in stroke patients .Stroke 1988;19 ( 5 ) 604- 607 PubMed Link to Article .", "label": "", "metadata": {}, "score": "65.85681"}
{"text": "van Swieten JCKoudstaal PJVisser MCSchouten HJvan Gijn J Interobserver agreement for the assessment of handicap in stroke patients .Stroke 1988;19 ( 5 ) 604- 607 PubMed Link to Article .", "label": "", "metadata": {}, "score": "65.85681"}
{"text": "Serum uric acid levels increased approximately 0.6 mg / dL from baseline on Ticagrelor and approximately 0.2 mg / dL on Clopidogrel in PLATO .The difference disappeared within 30 days of discontinuing treatment .", "label": "", "metadata": {}, "score": "65.88185"}
{"text": "24 These findings support the view that that people with diabetes may not simply be a subgroup of patients at high risk of cardiovascular events but a separate entity , with additional factors playing an important part in determining the efficacy of treatment .", "label": "", "metadata": {}, "score": "65.969795"}
{"text": "The aim of the Dutch Adverse Event Study was to measure a national incidence rate for hospital AEs .An in - depth analysis of surgical AEs based on the national study is hampered by the small numbers of AEs for some sub categories .", "label": "", "metadata": {}, "score": "66.02171"}
{"text": "For over half a century , oral anticoagulant therapy with vitamin K antagonists has proven its value in the primary and secondary prevention of arterial thromboembolism .", "label": "", "metadata": {}, "score": "66.04409"}
{"text": "Hospital - incurred patient injury ( Permanent or temporary injury obtained ( acquired ) during index admission ) .Adverse drug reaction .Unplanned transfer from general care to ( an ) intensive care ( unit ) .", "label": "", "metadata": {}, "score": "66.05286"}
{"text": "Although ASA was associated with a reduction in the risk of VTE , the results were less pronounced than those observed for all dosing strategies of VKA and the new oral anticoagulants .", "label": "", "metadata": {}, "score": "66.15505"}
{"text": "Major bleed - fatal / life - threatening .Major bleed - other .Any one of the following : significantly disabling ( e.g. , intraocular with permanent vision loss ) ; clinically overt or apparent bleeding associated with a decrease in Hb of 3 g / dL ; transfusion of 2 - 3 units ( whole blood or PRBCs ) for bleeding .", "label": "", "metadata": {}, "score": "66.21867"}
{"text": "Treatment - emergent [ after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication ( referred to as time window : 2 days ) ] events and all events post randomization were reported .", "label": "", "metadata": {}, "score": "66.236374"}
{"text": "10.1097/SLA.0b013e3180f61b09 .View Article .Grantcharov TP , Bardam L , Funch - Jensen P , Rosenberg J : Learning curves and impact of previous operation expercience on performance on a virtual reality simulator to test laparoscopic surgical skills .", "label": "", "metadata": {}, "score": "66.248695"}
{"text": "Zegers M , de Bruijne MC , Wagner C , Hoonhout LHF , Waaijman R , Smits M , Hout FAG , Zwaan L , Christiaans - Dingelhoff , Timmermans DRM , Groenewegen PP , van der Wal G : Adverse events and potentially preventable deaths in Dutch hospitals .", "label": "", "metadata": {}, "score": "66.25843"}
{"text": "Table 6 shows the study results for the primary composite endpoint and the contribution of each component to the primary endpoint .Separate secondary endpoint analyses are shown for the overall occurrence of CV death , MI , and stroke and overall mortality . 1 Dosed at 90 mg bid . 2 Note : rates of first events for the components CV Death , MI and Stroke are the actual rates for first events for each component and do not add up to the overall rate of events in the composite endpoint .", "label": "", "metadata": {}, "score": "66.27551"}
{"text": "Dans AL , Connolly SJ , Wallentin L , Yang S , Nakamya J , Brueckmann M , et al .Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long - Term Anticoagulation Therapy ( RE - LY ) trial .", "label": "", "metadata": {}, "score": "66.2794"}
{"text": "For each AE , the surgeon reviewers could select one or more potential prevention strategy .The reviewers selected the causes and potential prevention strategies based on information in the patient record and on their perception of the situation [ 23 ] .", "label": "", "metadata": {}, "score": "66.32536"}
{"text": "View Article PubMed .Zegers M , de Bruijne MC , Wagner C , Groenewegen PP , Waaijman R , van der Wal G : Design of a retrospective patient record study on the occurrence of adverse events among patients in Dutch hospitals .", "label": "", "metadata": {}, "score": "66.341"}
{"text": "Web appendix 6 presents a detailed explanation for the potential discrepancy between ASA and placebo results .Results for most class level analyses also aligned with those reported previously in the treatment level analysis .", "label": "", "metadata": {}, "score": "66.3793"}
{"text": "No data exist with Ticagrelor regarding a hemostatic benefit of platelet transfusions .Drug Discontinuation .In PLATO , the rate of study drug discontinuation attributed to adverse reactions was 7.4 % for Ticagrelor and 5.4 % for Clopidogrel .", "label": "", "metadata": {}, "score": "66.4084"}
{"text": "Data sources Medline ( 1966-November 2008 ) , the Cochrane central register of controlled trials ( Cochrane Library 2008;issue 4 ) , and reference lists of retrieved articles .", "label": "", "metadata": {}, "score": "66.42172"}
{"text": "The study had enough power to detect significant effects of combined supplementation of EPA - DHA and ALA on the end - point ventricular arrhythmia - related events whether or not in combination with fatal MI .", "label": "", "metadata": {}, "score": "66.4403"}
{"text": "All surgical AEs related to ' other clinical management ' , the diagnostic process and discharge procedure were judged to be preventable .Table 4 .", "label": "", "metadata": {}, "score": "66.492615"}
{"text": "Surgical AEs by specialty and proportions with preventability or permanent disability ( including death ) .The AEs attributable to surgical specialties were classified by clinical procedure ( Table 4 ) .", "label": "", "metadata": {}, "score": "66.58069"}
{"text": "Meanwhile , a better understanding of the pathophysiological mechanisms involved in the response of platelets to aspirin may also contribute to the identification of those who are more likely to benefit from antiplatelet treatment .", "label": "", "metadata": {}, "score": "66.58811"}
{"text": "For this reason , the study results can easily be applied to day - to - day practice .Now that we have defined the presumed optimal intensity of oral anticoagulation for patients with mechanical heart valve prostheses , atrial fibrillation , and after myocardial infarction , testing these ranges in new clinical trials should be considered .", "label": "", "metadata": {}, "score": "66.64852"}
{"text": "Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction .Circulation 2004 ; 109 : 855 -60 .De Berardis G , Sacco M , Evangelista V , Filippi A , Giorda CB , Tognoni G , et al .", "label": "", "metadata": {}, "score": "66.66348"}
{"text": "The Alpha Omega Trial tested the hypothesis that an additional intake of 0.4 g / day of EPA - DHA or 1.9 g / day of ALA will reduce fatal CHD and ventricular arrhythmia - related events in stable postmyocardial infarction ( post - MI ) patients ( 6 ) .", "label": "", "metadata": {}, "score": "66.6679"}
{"text": "AEs with a high percentage of preventability were pressure ulcers , injury by mechanical / physical or chemical cause , fistula forming , shock , and ischemia / heart failure .", "label": "", "metadata": {}, "score": "66.69708"}
{"text": "Guyatt GH , Eikelboom JW , Gould MK , Garcia DA , Crowther M , Murad MH , et al .Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients : Antithrombotic Therapy and Prevention of Thrombosis , 9th ed .", "label": "", "metadata": {}, "score": "66.70657"}
{"text": "Discussion .General findings .In this study the incidence rate of surgical AEs is 3.6 % of all hospital admissions .Of all in - hospital AEs , 65 % were attributable to surgical specialties of which 41 % were considered to be preventable .", "label": "", "metadata": {}, "score": "66.80086"}
{"text": "Cohen MG , Filby SJ , Roe MT , Chen AY , Menon V , Stouffer GA , et al .The paradoxical use of cardiac catheterization in patients with non - ST - elevation acute coronary syndromes : lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC / AHA Guidelines ( CRUSADE ) quality improvement initiative .", "label": "", "metadata": {}, "score": "66.83516"}
{"text": "N Engl J Med 1999 ; 340 : 901 -7 .Agnelli G , Prandoni P , Santamaria MG , Bagatella P , Iorio A , Bazzan M , et al .", "label": "", "metadata": {}, "score": "66.90008"}
{"text": "Stroke Prevention in Reversible Ischemia Trial ( SPIRIT )Study Group , A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin .", "label": "", "metadata": {}, "score": "66.900986"}
{"text": "Stroke Prevention in Reversible Ischemia Trial ( SPIRIT )Study Group , A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin .", "label": "", "metadata": {}, "score": "66.900986"}
{"text": "Place holder to copy figure label and caption .Figure .International normalized ratio ( INR ) specific incidence rates .Rates are shown for patients with a mechanical heart valve ( A ) , atrial fibrillation ( B ) , and myocardial infarction ( C ) .", "label": "", "metadata": {}, "score": "66.95057"}
{"text": "Given the high degree of preventability of surgical AEs that resulted in injury by mechanical / physical or chemical cause , the frequently recommended prevention strategies were : more training ; improving procedures ; and quality assurance .", "label": "", "metadata": {}, "score": "66.96179"}
{"text": "Log in or register : .Download this article to citation manager .James Stefan K , Roe Matthew T , Cannon Christopher P , Cornel Jan H , Horrow Jay , Husted Steen et al .", "label": "", "metadata": {}, "score": "66.966324"}
{"text": "The reviewers selected all causes that contributed to the occurrence of the AE .They used a recognized taxonomy of root causes : the Eindhoven Classification Model of PRISMA - Medical , a root cause analysis tool [ 21 , 22 ] .", "label": "", "metadata": {}, "score": "66.97491"}
{"text": "8 Treatment was allocated according to a 2\u00d72 factorial design with vitamin E in three studies .8 9 22 Four studies were placebo controlled and double blinded . 8 9 17 21 Two studies 10 22 were open label .", "label": "", "metadata": {}, "score": "67.02954"}
{"text": "The major drawback of oral anticoagulant therapy is the increased risk of hemorrhage , which is associated with the intensity of anticoagulation and patient characteristics such as age and sex .", "label": "", "metadata": {}, "score": "67.068054"}
{"text": "Further studies in the \" real world \" setting are needed .Conclusions .The rates of recurrent VTE and major bleeding events should be taken into account when assessing the efficacy and safety of different treatment strategies for secondary prevention for VTE .", "label": "", "metadata": {}, "score": "67.132"}
{"text": "What is already known on this topic .Long term anticoagulation for the secondary prevention of venous thromboembolism remains controversial .Recently , novel oral anticoagulants and antiplatelet drugs have been evaluated for the secondary prevention of venous thromboembolism .", "label": "", "metadata": {}, "score": "67.162094"}
{"text": "For each AE , the reviewers indicated all consequences .In addition , the underlying causes of AEs were assessed .An AE arises often due to several causal factors , including technical , organisational , human , and patient - related factors .", "label": "", "metadata": {}, "score": "67.23287"}
{"text": "Unilever provided an unrestricted grant for distribution of trial margarines to the patients .The funding organizations had no role in the design of the study , data collection , data analysis , interpretation , writing of the report , or the decision to submit .", "label": "", "metadata": {}, "score": "67.333466"}
{"text": "27 The fact that our meta - analysis could not confirm this in trials of aspirin in only people with diabetes is possibly due to the trials themselves being underpowered to detect this relatively rare event .", "label": "", "metadata": {}, "score": "67.37991"}
{"text": "6- or 12-month study treatment period ] [ Designated as safety issue : No ] .Percentage of Participants With Recurrent VTE ( PE or DVT ) Until the Intended End of Study Treatment [ Time Frame :", "label": "", "metadata": {}, "score": "67.383865"}
{"text": "The reviewers practiced on examples of cases and with the review forms .They were provided with a review manual in which the research protocol , instruments , and definitions were defined [ 17 ] .", "label": "", "metadata": {}, "score": "67.40838"}
{"text": "The dose of aspirin used in the trials ranged from 100 mg on an alternate day basis 8 up to 650 mg daily .21 Follow - up ranged from 3.6 22 to 10.1 years . 8 Compliance with treatment ranged between 50 % 9 and 92 % .", "label": "", "metadata": {}, "score": "67.4261"}
{"text": "We use the data from this study in our paper in order to present a detailed description of surgical AEs .Our research questions were : ( 1 ) what is the incidence , consequences , nature , and preventability of surgical AEs among hospitalized patients , and ( 2 ) what are the causes of , and potential prevention strategies for , surgical AEs ?", "label": "", "metadata": {}, "score": "67.43341"}
{"text": "Eur Heart J 2009 ; 30 : 645 -54 .Cannon CP , Harrington RA , James S , Ardissino D , Becker RC , Emanuelsson H , et al .", "label": "", "metadata": {}, "score": "67.46637"}
{"text": "The curves separate by 30 days ( RRR 12 % ) and continue to diverge throughout the 12 month treatment period ( RRR 16 % ) .", "label": "", "metadata": {}, "score": "67.49325"}
{"text": "Chan MY , Mahaffey KW , Sun LJ , Pieper KS , White HD , Aylward PE , et al .Prevalence , predictors , and impact of conservative medical management for patients with non - ST - segment elevation acute coronary syndromes who have angiographically documented significant coronary disease .", "label": "", "metadata": {}, "score": "67.50806"}
{"text": "10.1001/jama.288.4.501 .View Article PubMed .Song F , Glenny AM : Antimicrobial prophylaxis in colorectal surgery : a systematic review of randomized controlled trials .", "label": "", "metadata": {}, "score": "67.515594"}
{"text": "Italian Study on Complications of Oral Anticoagulant Therapy , Bleeding complications of oral anticoagulant treatment : an inception - cohort , prospective collaborative study ( ISCOAT ) .", "label": "", "metadata": {}, "score": "67.59639"}
{"text": "Italian Study on Complications of Oral Anticoagulant Therapy , Bleeding complications of oral anticoagulant treatment : an inception - cohort , prospective collaborative study ( ISCOAT ) .", "label": "", "metadata": {}, "score": "67.59639"}
{"text": "Therefore , post - MI patients with diabetes are a suitable group to test the hypothesis that n-3 fatty acids protect against fatal CHD and ventricular arrhythmia - related events .", "label": "", "metadata": {}, "score": "67.657394"}
{"text": "CONCLUSIONS Our results suggest that low - dose supplementation of n-3 fatty acids exerts a protective effect against ventricular arrhythmia - related events in post - MI patients with diabetes .", "label": "", "metadata": {}, "score": "67.69766"}
{"text": "In trial margarines for active treatment groups , oleic acid was exchanged for the different n-3 fatty acids .The ratio of EPA to DHA in the spreads was 3:2 .", "label": "", "metadata": {}, "score": "67.70541"}
{"text": "Ugeskr Laeger .PubMed .Thomas EJ , Studdert DM , Burstin HR , Orav EJ , Zeena T , Williams EJ , Howard KM , Weiler PC , Brennan TA : Incidence and types of adverse events and negligent care in Utah and Colorado .", "label": "", "metadata": {}, "score": "67.74537"}
{"text": "Adjusted continuity corrections of 0.5 were used in the analyses , resulting in uncertain effect estimates for rivaroxaban .Therefore , larger studies of longer duration are needed to provide more definitive conclusions regarding the comparative risk of bleeding with rivaroxaban with other treatments ( web appendix 9 ) .", "label": "", "metadata": {}, "score": "67.81811"}
{"text": "Main categories of causes of surgical AEs compared with other AEs .H indicates human ; O , organization ; T , technical ; PR , patient related ; and Oth , other . a Corrected for the over - representation of deceased patients and hospital type .", "label": "", "metadata": {}, "score": "67.834564"}
{"text": "2004 , 328 : 199 - 10.1136/bmj.328.7433.199 .PubMed Central View Article PubMed .Schioler T , Lipczak H , Pedersen BL , Mogensen TS , Bech KB , Stockmarr A , Svenning AR , Frolich A , Danish Adverse Event Study : [ Incidence of adverse events in hospitals .", "label": "", "metadata": {}, "score": "67.93153"}
{"text": "N Engl J Med 1995;333 ( 1 )5- 10 PubMed Link to Article .Cannegieter SCRosendaal FRWintzen ARvan der Meer FJVandenbroucke JPBri\u00ebt E Optimal oral anticoagulant therapy in patients with mechanical heart valves .", "label": "", "metadata": {}, "score": "67.98568"}
{"text": "N Engl J Med 1995;333 ( 1 )5- 10 PubMed Link to Article .Cannegieter SCRosendaal FRWintzen ARvan der Meer FJVandenbroucke JPBri\u00ebt E Optimal oral anticoagulant therapy in patients with mechanical heart valves .", "label": "", "metadata": {}, "score": "67.98568"}
{"text": "2007 , 334 ( 7584 ) : 79 - 10.1136/bmj.39031.507153 .AE .View Article .Neale G , Chapman EJ , Hoare J , Olsen S : Recognising adverse events and critical incidents in medical practice in a district general hospital .", "label": "", "metadata": {}, "score": "67.98574"}
{"text": "Predicting the extent of heterogeneity in meta - analysis , using empirical data from the Cochrane Database of Systematic Reviews .Int J Epidemiol 2012 ; 41 : 818 -27 .", "label": "", "metadata": {}, "score": "68.0713"}
{"text": "In the US 57 % of patients received doses above 100 mg and 54 % received doses above 300 mg .Figure 10 shows overall results by median aspirin dose .", "label": "", "metadata": {}, "score": "68.07775"}
{"text": "Percentage of Participants With Recurrent VTE ( PE or DVT )During Observational Period [ Time Frame : 30 days observational period after last intake of study medication ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "68.10853"}
{"text": "The duration of oral anticoagulant therapy after a second episode of venous thromboembolism .N Engl J Med 1997 ; 336 : 393 -8 .Kearon C , Gent M , Hirsh J , Weitz J , Kovacs MJ , Anderson DR , et al .", "label": "", "metadata": {}, "score": "68.18824"}
{"text": "The analysis includes ximelagatran to improve precision of effect estimates ; however , the results are not reported because ximelagatran is not commercially available .We constructed all evidence networks using NodeXL .", "label": "", "metadata": {}, "score": "68.19975"}
{"text": "10.1016/S0002 - 9610(02)01213 - 8 .View Article PubMed .Scheeres DE , Mellinger JD , Brasser BA , Davies AT : Animate advanced laparoscopic courses improve resident operative performance .", "label": "", "metadata": {}, "score": "68.292175"}
{"text": "All cause mortality .Side effects : bleeding , gastrointestinal symptoms , cancer .There was no statistically significant increase in the risk of any of these outcomes with aspirin therapy compared with placebo or no treatment .", "label": "", "metadata": {}, "score": "68.30623"}
{"text": "The percentages of those patients who bled are shown in Table 2 .Rates were very high but similar for Ticagrelor and Clopidogrel .Although the platelet inhibition effect of Ticagrelor has a faster offset than Clopidogrel in in vitro tests and Ticagrelor is a reversibly binding P2Y12 inhibitor , PLATO did not show an advantage of Ticagrelor compared to Clopidogrel for CABG -related bleeding .", "label": "", "metadata": {}, "score": "68.36348"}
{"text": "If surgical AEs are easier to recognize in medical records , the difference between surgical and non - surgical AEs may be overestimated .Record review may not be the most accurate method to get an insight into the technical and organizational causal factors .", "label": "", "metadata": {}, "score": "68.45517"}
{"text": "GISSI - Prevenzione Investigators ( Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico ) .Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction : results of the GISSI - Prevenzione trial .", "label": "", "metadata": {}, "score": "68.45886"}
{"text": "All indications for implantable cardioverter defibrillator placement could be retrieved and verified from hospital discharge letters or by telephone with the departments of cardiology where the placements had taken place .", "label": "", "metadata": {}, "score": "68.538376"}
{"text": "9 10 21 For the remaining three trials data for the whole study sample were available but no specific information on the subset of participants with diabetes was reported .", "label": "", "metadata": {}, "score": "68.570496"}
{"text": "8 42 Recurrent VTE might be fatal or lead to important clinical complications such as post - thrombotic syndrome and chronic thromboembolic pulmonary hypertension , which are associated with a substantial reduction in quality of life .", "label": "", "metadata": {}, "score": "68.58164"}
{"text": "The consequences of surgical AEs were also classified by the type of injury , such as : bleeding , infection , shock , thrombosis , necrosis , fistula forming , and abnormal wound healing .", "label": "", "metadata": {}, "score": "68.613144"}
{"text": "MTR , JK , and JM participated in data gathering and interpretation and revision of the report .SS was involved in data analysis and revision of the report .", "label": "", "metadata": {}, "score": "68.725525"}
{"text": "De Queiroz Fernandes Araujo JO , Veloso HH , Braga De Paiva JM , Filho MW , Vincenzo De Paola AA .Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions : a meta - analysis of randomized , controlled trials .", "label": "", "metadata": {}, "score": "68.845505"}
{"text": "12 However , in contrast to the significant benefit of abciximab that has been shown in patients with acute coronary syndrome having percutaneous coronary intervention , abciximab increased the incidence of bleeding and did not reduce ischaemic end points in this trial that encouraged an early non - invasive management strategy .", "label": "", "metadata": {}, "score": "68.85426"}
{"text": "Hirsh JDalen JAnderson DR et al .Oral anticoagulants : mechanism of action , clinical effectiveness , and optimal therapeutic range .Chest 2001;119 ( 1 ) ( ( suppl ) ) 8S- 21S PubMed Link to Article .", "label": "", "metadata": {}, "score": "68.88641"}
{"text": "Hirsh JDalen JAnderson DR et al .Oral anticoagulants : mechanism of action , clinical effectiveness , and optimal therapeutic range .Chest 2001;119 ( 1 ) ( ( suppl ) ) 8S- 21S PubMed Link to Article .", "label": "", "metadata": {}, "score": "68.88641"}
{"text": "The search protocol is documented online in the PROSPERO registry ( CRD42013003489 ) .Web appendix 1 includes the systematic search strategy .There were no restrictions on language , publication year , or type of publication .", "label": "", "metadata": {}, "score": "68.96195"}
{"text": "The median time from onset of symptoms to randomisation was 16.6 ( interquartile range 9.1 - 22.0 ) hours , and the duration of the randomised treatment was 276 ( 175 - 365 ) days .", "label": "", "metadata": {}, "score": "69.10079"}
{"text": "Endocr Pract 2007 ; 13 ( suppl 1 ) : 1 -68 .Nicolucci A , De Berardis G , Sacco M , Tognoni G. AHA / ADA vs ESC / EASD recommendations on aspirin as a primary prevention strategy in people with diabetes : how the same data generate divergent conclusions .", "label": "", "metadata": {}, "score": "69.145035"}
{"text": "Secondary outcome measures included fatal recurrent VTE and fatal bleeding episodes .Fatal recurrent VTE was diagnosed by autopsy , a high probability ventilation / perfusion scan or new intraluminal filling defect detected on computed tomography or venography before death , or a high clinical suspicion of fatal pulmonary embolism as defined by the investigators of each study .", "label": "", "metadata": {}, "score": "69.15485"}
{"text": "The 95 % confidence limits that are shown do not take into account how many comparisons were made , nor do they reflect the effect of a particular factor after adjustment for all other factors .", "label": "", "metadata": {}, "score": "69.18695"}
{"text": "The 95 % confidence limits that are shown do not take into account how many comparisons were made , nor do they reflect the effect of a particular factor after adjustment for all other factors .", "label": "", "metadata": {}, "score": "69.18695"}
{"text": "There was no statistically significant reduction in the risk of stroke with aspirin in men and in women , but there were opposite trends across these two subgroups - that is , an increased risk in men and a decreased risk in women .", "label": "", "metadata": {}, "score": "69.25682"}
{"text": "MAR is the recipient of a Career Scientist Award from the Heart and Stroke Foundation of Ontario .PSW is a recipient of a Canada research chair in venous thromboembolism .", "label": "", "metadata": {}, "score": "69.26038"}
{"text": "The risk of recurrent VTE and major bleeding are fundamental considerations in a doctor 's recommendation for secondary prevention of VTE and which agent to choose .", "label": "", "metadata": {}, "score": "69.28374"}
{"text": "Lilford RJ , Mohammed MA , Braunholtz D , Hofer TP : The measurement of active errors : methodological issues .Qual Saf Health Care .", "label": "", "metadata": {}, "score": "69.40795"}
{"text": "12 Department of Cardiovascular Science , University of Sheffield , Sheffield , UK .Accepted 21 April 2011 .Abstract .Objective To evaluate efficacy and safety outcomes in patients in the PLATelet inhibition and patient Outcomes ( PLATO ) trial who at randomisation were planned for a non - invasive treatment strategy .", "label": "", "metadata": {}, "score": "69.40822"}
{"text": "Significant versus insignificant coronary disease among patients who had in - hospital angiography .Patients with no significant disease had numerically lower event rates compared with those who were discovered to have significant disease .", "label": "", "metadata": {}, "score": "69.429886"}
{"text": "For statistical analysis 2 : from randomisation to end of ptp , planned to be up to day 224 . ][ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "69.47652"}
{"text": "For statistical analysis 2 : from randomisation to end of ptp , planned to be up to day 224 . ][ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "69.47652"}
{"text": "For statistical analysis 2 : from randomisation to end of ptp , planned to be up to day 224 . ][ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "69.47652"}
{"text": "Mehta SR , Yusuf S , Peters RJ , Bertrand ME , Lewis BS , Natarajan MK , et al .Effects of pretreatment with clopidogrel and aspirin followed by long - term therapy in patients undergoing percutaneous coronary intervention : the PCI - CURE study .", "label": "", "metadata": {}, "score": "69.50714"}
{"text": "Hazard ratios ( HRs ) and 95 % CIs were computed for ventricular arrhythmia - related events , fatal MI , and the combination of these two end points , using Cox proportional hazard models .", "label": "", "metadata": {}, "score": "69.62698"}
{"text": "An increasing amount of data suggest that factors specific to diabetes , including hyperglycaemia , hyperinsulinaemia , increased oxidative stress , and advanced glycosylation end products , may up - regulate humoral , cellular inflammatory , and thrombogenic reactions thereby playing a part in atherothrombosis .", "label": "", "metadata": {}, "score": "69.71651"}
{"text": "The determination and implementation of the optimal intensity represents a way to improve the safety of oral anticoagulant therapy .We previously developed a method to determine the optimal intensity level in observational studies , 10 which was subsequently applied for various indications .", "label": "", "metadata": {}, "score": "69.76296"}
{"text": "What this study adds .This meta - analysis suggests that the benefit of aspirin in the primary prevention of major cardiovascular events or death in people with diabetes may be lower than in other high risk populations .", "label": "", "metadata": {}, "score": "69.785225"}
{"text": "This is a multicenter , randomized , double - blind , placebo - controlled , event - driven , superiority study for efficacy .Patients with confirmed symptomatic DVT ( deep vein thrombosis ) or PE ( pulmonary embolism ) who completed 6 or 12 months of treatment with rivaroxaban or VKA ( vitamin K antagonist ) are eligible for this trial ( Einstein - Extension study ) .", "label": "", "metadata": {}, "score": "69.78692"}
{"text": "Study selection .Using a structured question format to aid our literature search strategy , we reviewed all abstracts .Potentially relevant articles were reviewed in full length to ensure that they satisfied all of the following criteria : .", "label": "", "metadata": {}, "score": "69.83348"}
{"text": "Lancet 1998 ; 351 : 1755 -62 .Critical Leg Ischaemia Prevention Study ( CLIPS ) Group , Catalano M , Born G , Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease : randomized , double - blind trial .", "label": "", "metadata": {}, "score": "69.91419"}
{"text": "The American College of Chest Physicians currently recommends considering long term treatment in patients with unprovoked VTE and low risk of bleeding episodes . 8However , physicians and patients are often reluctant to consider long term treatment with VKA owing to the risks of bleeding , the need for regular monitoring , and lifestyle adjustments as long as treatment is continued .", "label": "", "metadata": {}, "score": "69.93404"}
{"text": "Arch Intern Med 1994;154 ( 13 )1449- 1457 PubMed Link to Article .van Es RFJonker JJVerheugt FWDeckers JWGrobbee DEAntithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 ( ASPECT-2 ) Research Group , Aspirin and coumadin after acute coronary syndromes ( the ASPECT-2 study ) : a randomised controlled trial .", "label": "", "metadata": {}, "score": "70.02704"}
{"text": "9 For the initial treatment of VTE , there was no difference observed in the rates of recurrent VTE between patients treated with the new oral anticoagulants or VKA .", "label": "", "metadata": {}, "score": "70.07103"}
{"text": "Marieke Torn , MD ; Suzanne C. Cannegieter , MD ; Ward L. E. M. Bollen , MD ; Felix J. M. van der Meer , MD ; Ernst E. van der Wall , MD ; Frits R. Rosendaal , MD , PhD .", "label": "", "metadata": {}, "score": "70.21646"}
{"text": "N Engl J Med 2003 ; 348 : 1425 -34 .Kearon C , Ginsberg JS , Kovacs MJ , Anderson DR , Wells PS , Julian JA , et al .", "label": "", "metadata": {}, "score": "70.28064"}
{"text": "Liver disease expected to have any potential impact on survival .Patients who have developed transaminase elevations upon exposure to ximelagatran .Severe renal impairment .", "label": "", "metadata": {}, "score": "70.30281"}
{"text": "Surgery .10.1067/msy.1999.98664 .View Article PubMed .Kable AK , Gibberd RW , Spigelman AD : Adverse events in surgical patients in Australia .", "label": "", "metadata": {}, "score": "70.445984"}
{"text": "Ogawa H , Nakayama M , Morimoto T , Uemura S , Kanauchi M , Doi N , et al .Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes ( JPAD )", "label": "", "metadata": {}, "score": "70.48529"}
{"text": "Rodbard HW , Blonde L , Braithwaite SS , Brett EM , Cobin RH , Handelsman Y , et al . ; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force .", "label": "", "metadata": {}, "score": "70.52841"}
{"text": "However , evidence - based solutions to reduce surgical AEs are increasingly available .Interventions directed at human causes are recommended to improve the safety of surgical care .", "label": "", "metadata": {}, "score": "70.62215"}
{"text": "However , standard adjusted dose VKA was associated with an increased risk of major bleeding compared with placebo or observation .These risks for recurrent VTE and major bleeding events are key pieces of information to help doctor assess the benefit - harm balance of the various agents in secondary prevention and tailor their therapeutic approaches accordingly .", "label": "", "metadata": {}, "score": "70.701416"}
{"text": "Evangelista V , Totani L , Rotondo S , Lorenzet R , Tognoni G , De Berardis G , et al .Prevention of cardiovascular disease in type-2 diabetes : how to improve the clinical efficacy of aspirin .", "label": "", "metadata": {}, "score": "70.71109"}
{"text": "CONCLUSIONS .Low - dose supplementation of n-3 fatty acids EPA - DHA plus ALA significantly reduced ventricular arrhythmia - related events in post - MI patients with diabetes .", "label": "", "metadata": {}, "score": "70.711334"}
{"text": "The primary endpoint was the composite of first occurrence of CV death , non - fatal MI and non - fatal stroke .CV death and all - cause mortality were assessed as secondary endpoints .", "label": "", "metadata": {}, "score": "70.760284"}
{"text": "Benn J , Koutantji M , Wallace L , Spurgeon P , Rejman M , Healey A , Vincent C : Feedback from incident reporting : information and action to improve patient safety .", "label": "", "metadata": {}, "score": "70.77106"}
{"text": "Both end points included fatal cardiac arrest and sudden death .In the present analysis , mutually exclusive definitions will be used ; therefore , fatal CHD is limited to fatal MI .", "label": "", "metadata": {}, "score": "70.77628"}
{"text": "Physicians who complete the CME course and score at least 80 % correct on the quiz are eligible for AMA PRA Category 1 Credit TM .", "label": "", "metadata": {}, "score": "70.82956"}
{"text": "Recent data are needed to provide insight into the scale , nature , causes and preventability of surgical AEs and to identify those prevention strategies which can reduce the main causes of surgical AEs .", "label": "", "metadata": {}, "score": "70.91518"}
{"text": "The other consequences of surgical AEs were more severe compared to other types of AEs .Consequences of surgical AEs compared with other AEs .I / T indicates intervention / treatment ; DD , disability at discharge ; PH , prolonged hospital stay ; RA , readmission to the hospital ; D , death ; Out , extra outpatient care ; and Oth , other . a Corrected for the over - representation of deceased patients and hospital type .", "label": "", "metadata": {}, "score": "70.97798"}
{"text": "Experiments in obese mice showed that activation of the G protein - coupled receptor 120 ( GPR120 ) by EPA and DHA inhibited multiple inflammation cascades and reversed insulin resistance caused by a high - fat diet ( 24 ) .", "label": "", "metadata": {}, "score": "70.99379"}
{"text": "The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology ( ESC ) and of the European Association for the Study of Diabetes ( EASD ) .", "label": "", "metadata": {}, "score": "71.012405"}
{"text": "Sacco M , Pellegrini F , Roncaglioni MC , Avanzini F , Tognoni G , Nicolucci A. Primary prevention of cardiovascular events with low - dose aspirin and vitamin E in type 2 diabetic patients : results of the Primary Prevention Project ( PPP ) trial .", "label": "", "metadata": {}, "score": "71.126816"}
{"text": "The effects of age , gender , ethnicity , renal impairment and mild hepatic impairment on the pharmacokinetics of ticagrelor are presented in Figure 5 .", "label": "", "metadata": {}, "score": "71.14334"}
{"text": "A possible protective effect of EPA - DHA on fatal MI would be in accord with the results of a prospective study carried out in postmenopausal women ( 20 ) .", "label": "", "metadata": {}, "score": "71.14935"}
{"text": "Reviewer training .The hospital records of the selected admissions were reviewed by a team of 66 nurses and 55 medical specialists .An additional expert panel of 18 medical specialists from several sub specialties was recruited to offer expert advice about accepted clinical practice during the review process .", "label": "", "metadata": {}, "score": "71.20201"}
{"text": "Although evidence of the effect of fish consumption and EPA - DHA supplementation on fatal CHD in patients with diabetes is small , the available data are compatible with the hypothesis that EPA - DHA may protect against fatal CHD .", "label": "", "metadata": {}, "score": "71.25034"}
{"text": "Counts of patients having a centrally adjudicated definite ACS during intake of active study drug , after stopping active study drug and before or without intake of active study drug , according to treatment group .", "label": "", "metadata": {}, "score": "71.30371"}
{"text": "PEGASUS .The PEGASUS TIMI-54 study was a 21162-patient , randomized , double - blind , placebo - controlled , parallel - group study .", "label": "", "metadata": {}, "score": "71.327156"}
{"text": "Number in group have been reported as provided by trialists or estimated from any available data in the publications .Discussion .A clear benefit of aspirin in the primary prevention of major cardiovascular events or mortality in people with diabetes could not be identified in our meta - analysis .", "label": "", "metadata": {}, "score": "71.33292"}
{"text": "Introduction .Venous thromboembolism ( VTE ) , comprising deep vein thrombosis , pulmonary embolism , or both , is the third most common cardiovascular disorder . 1 2 3 4 5 6 7 VTE is a potentially fatal yet preventable and treatable condition with the use of anticoagulation therapy .", "label": "", "metadata": {}, "score": "71.3385"}
{"text": "Hylek EMSkates SJSheehan MASinger DE An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation .N Engl J Med 1996;335 ( 8) 540- 546 PubMed Link to Article .", "label": "", "metadata": {}, "score": "71.34294"}
{"text": "Hylek EMSkates SJSheehan MASinger DE An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation .N Engl J Med 1996;335 ( 8) 540- 546 PubMed Link to Article .", "label": "", "metadata": {}, "score": "71.34294"}
{"text": "Fatal recurrent VTE and fatal bleeding episodes .Fatal recurrent VTE and fatal bleeding episodes were rare .Web appendix 10 reports pooled rates of fatal events .", "label": "", "metadata": {}, "score": "71.38317"}
{"text": "Ottervanger JP , Armstrong P , Barnathan ES , Boersma E , Cooper JS , Ohman EM , et al .Association of revascularisation with low mortality in non - ST elevation acute coronary syndrome , a report from GUSTO IV - ACS .", "label": "", "metadata": {}, "score": "71.63961"}
{"text": "On treatment : after intake of first tablet of study medication as randomized but not more than 1 day after stop of study medication ( referred to as time window : 1 day ) .", "label": "", "metadata": {}, "score": "71.67611"}
{"text": "The reviewers were also updated with the latest insights about the review process .These training sessions were repeated frequently during the data collection period .", "label": "", "metadata": {}, "score": "71.68679"}
{"text": "Implications for practice .Interventions to reduce surgical AEs based on evidence - based studies , systematic reviews and ongoing clinical trials are increasingly available .", "label": "", "metadata": {}, "score": "71.71786"}
{"text": "Number of Participants With Acute Coronary Syndrome ( ACS )[ Time Frame : From first intake of study drug to end of study conduct ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "71.758965"}
{"text": "10.1056/NEJM199102073240604 .View Article PubMed .Davis P , Lay - Yee R , Briant R , Ali W , Scott A , Schug S : Adverse events in New Zealand public hospitals I : occurrence and impact .", "label": "", "metadata": {}, "score": "71.82794"}
{"text": "PE satisfying at least one of the following criteria : Haemodynamic instability , embolectomy is indicated or performed , thrombolytic therapy is indicated or performed , or suspected source of PE is other than the legs .", "label": "", "metadata": {}, "score": "71.84374"}
{"text": "3 - 5 Despite the development of new anticoagulants as direct thrombin inhibitors , vitamin K antagonists remain the keystone of anticoagulant therapy in most patients .", "label": "", "metadata": {}, "score": "71.87399"}
{"text": "It is notable , however , that aspirin dose predicts outcome in both regions with a similar pattern , and that the pattern is similar for the two major components of the primary endpoint , CV death and non - fatal MI .", "label": "", "metadata": {}, "score": "71.95673"}
{"text": "Comparison with existing data .7 The potential reasons for lower efficacy of aspirin in people with diabetes compared with other high risk populations have been explored .", "label": "", "metadata": {}, "score": "71.996414"}
{"text": "ASA monotherapy poses a safer alternative to the combination of ASA and a new oral anticoagulant , which have shown higher risks of bleeding .47 48 49 Secondly , the new oral anticoagulants have not been adequately studied to inform on benefits and harms of extending their use beyond one year for long term secondary prevention of recurrent VTE .", "label": "", "metadata": {}, "score": "72.01819"}
{"text": "For fatal MI , the Kaplan - Meier curves did not differ significantly among the four groups ( Fig . 1 B ) .After adjustment for confounders , the strongest , although not significant , effect was observed for EPA - DHA plus ALA ( HR 0.53 ; 95 % CI 0.15 - 1.81 ; Table 2 ) .", "label": "", "metadata": {}, "score": "72.04982"}
{"text": "Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography , percutaneous coronary intervention ( PCI ) , CABG , or other surgery .", "label": "", "metadata": {}, "score": "72.10687"}
{"text": "Median exposure to study drug was 277 days .About half of the patients received pre - study clopidogrel and about 99 % of the patients received aspirin at some time during PLATO .", "label": "", "metadata": {}, "score": "72.13478"}
{"text": "Surgical AEs classed as ' other clinical management ' ( 2.8 % ) were related to insufficient post operative care , for example inadequate administration of gastro - enteral feeding resulting in aspiration or a liver abscess drain becoming disconnected , resulting in sepsis .", "label": "", "metadata": {}, "score": "72.15603"}
{"text": "Chest 2012 ; 141 : e185 -94S. .Kahn SR , Shrier I , Julian JA , Ducruet T , Arsenault L , Miron MJ , et al .", "label": "", "metadata": {}, "score": "72.17805"}
{"text": "Women who consumed fish five or more times per week had a 64 % lower risk of CHD mortality compared with those who consumed fish less than once per month .", "label": "", "metadata": {}, "score": "72.2551"}
{"text": "Diabetes Care 2007 ; 30 : 1241 -7 .Lee CD , Folsom AR , Pankow JS , Brancati FL .Atherosclerosis Risk in Communities ( ARIC )", "label": "", "metadata": {}, "score": "72.31089"}
{"text": "10.1016/j.amjsurg.2005.07.018 .View Article PubMed .Leape LL , Berwick DM , Bates DW : What practices will most improve safety ?Evidence - based medicine meets patient safety .", "label": "", "metadata": {}, "score": "72.373"}
{"text": "View Article .Altman DG : Practical Statistics for Medical Research .1991 , London : Chapman & Hall .Longo DR , Hewett JE , Ge B , Schubert S : The Long Road to Patient Safety A Status Report on Patient Safety Systems .", "label": "", "metadata": {}, "score": "72.38838"}
{"text": "The results of a recently published collaborative meta - analysis by the Antithrombotic Trialists ' Collaboration argue in that direction , suggesting a limited efficacy of aspirin in primary prevention in people without diabetes .", "label": "", "metadata": {}, "score": "72.39273"}
{"text": "Although the efficacy profiles of the two regimens were similar , the lower dose had lower risks of bleeding and dyspnea .Table 8 shows the results for the 60 mg plus aspirin regimen vs. aspirin alone .", "label": "", "metadata": {}, "score": "72.41246"}
{"text": "Two studies each treated patients with ASA 17 18 or dabigatran 20 whereas one study each assessed rivaroxaban , apixaban ( two doses ) , and ximelagatran .", "label": "", "metadata": {}, "score": "72.42438"}
{"text": "For specific in vivo effects on the pharmacokinetics of simvastatin , atorvastatin , ethinyl estradiol , levonorgesterol , tolbutamide , digoxin and cyclosporine , see Figure 7 .", "label": "", "metadata": {}, "score": "72.52205"}
{"text": "Previous record review studies that reported on surgical AEs in detail are now more than ten years old .Since then surgical technology and quality assurance have changed rapidly .", "label": "", "metadata": {}, "score": "72.52775"}
{"text": "After years of improvements in patient safety [ 25 ] the scale of surgical AEs is still considerable .Surgical care is developing continuously .Over the past decades , the number and complexity of diagnostic procedures and therapeutic interventions have increased markedly .", "label": "", "metadata": {}, "score": "72.54135"}
{"text": "The effects of age , gender , ethnicity , renal impairment and mild hepatic impairment on the pharmacokinetics of ticagrelor are presented in Figure 4 .", "label": "", "metadata": {}, "score": "72.59439"}
{"text": "20 35 39 Future direct comparison trials are needed to confirm our findings .In addition , limited data were available for some of the anticoagulant agents to include in the analysis .", "label": "", "metadata": {}, "score": "72.59892"}
{"text": "Although the results in subgroups based on post - randomisation clinical data and treatment options have to be interpreted with caution , the benefit of ticagrelor compared with clopidogrel was consistent with the overall trial results .", "label": "", "metadata": {}, "score": "72.669464"}
{"text": "Davis P , Lay - Yee R , Briant R , Ali W , Scott A , Schug S : Adverse events in New Zealand public hospitals II : preventability and clinical context .", "label": "", "metadata": {}, "score": "72.68446"}
{"text": "Acquisition of data : Torn , Bollen , and van der Meer .Analysis and interpretation of data : Torn , Cannegieter , van der Meer , van der Wall , and Rosendaal .", "label": "", "metadata": {}, "score": "72.71237"}
{"text": "Atrial Fibrillation Investigators , Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation : analysis of pooled data from five randomized controlled trials .", "label": "", "metadata": {}, "score": "72.80093"}
{"text": "deep vein thrombosis or pulmonary embolism treated for a minimum of three months with anticoagulant treatment .Patients randomised to receive an antiplatelet drug ( ASA ) , an oral anticoagulant drug ( VKA , rivaroxaban , apixaban , dabigatran , or ximelagatran ) , or a placebo or observation for secondary prevention of VTE .", "label": "", "metadata": {}, "score": "72.81549"}
{"text": "All authors had full access to the data and take responsibility for the integrity of the data and accuracy of the analysis .MC is guarantor .", "label": "", "metadata": {}, "score": "72.862"}
{"text": "Qual Saf Health Care . 10.1136/qshc.2007.025924 .View Article PubMed .Marang - van de Mheen PJ , Stadlander MC , Kievit J : Adverse outcomes in surgical patients : implementation of a nationwide reporting system .", "label": "", "metadata": {}, "score": "72.93586"}
{"text": "JAMA 2006 ; 295 : 306 -13 .Avogaro A , Giorda C , Maggini M , Mannucci E , Raschetti R , Lombardo F , et al .", "label": "", "metadata": {}, "score": "72.94917"}
{"text": "If all authors have none , check \" No potential conflicts or relevant financial interests \" in the box below .Please also indicate any funding received in support of this work .", "label": "", "metadata": {}, "score": "72.985596"}
{"text": "The common denominator of this end point is the high risk of ventricular fibrillation .These discrepant results suggest that n-3 fatty acids may reduce primary arrhythmias in post - MI patients with diabetes with a low ejection fraction but not secondary arrhythmias in cardiac patients with cardioverter defibrillators .", "label": "", "metadata": {}, "score": "73.06799"}
{"text": "An intervention study carried out in Japan showed that diabetic patients who were supplemented with 1.8 g EPA per day in contrast with the control group did not show an increase in intima - media thickness during 2.1 years of follow - up ( 21 ) .", "label": "", "metadata": {}, "score": "73.08196"}
{"text": "Cell culture studies provide evidence that EPA and DHA are potential ligands for PPAR - \u03b3 activation ( 22 ) .Recently published results of an in vivo experiment suggested that fish oil increases the expression of glucose uptake genes , leading to reduced glucose levels ( 23 ) .", "label": "", "metadata": {}, "score": "73.11199"}
{"text": "Abstract .Objective To summarise and compare the efficacy and safety of various oral anticoagulants ( dabigatran , rivaroxaban , apixaban , and vitamin K antagonists ) and antiplatelet agents ( acetylsalicylic acid ) for the secondary prevention of venous thromboembolism .", "label": "", "metadata": {}, "score": "73.18573"}
{"text": "SKJ declares research grants and advisory board fees from AstraZeneca and honorariums from AstraZeneca , Bristol - Myers Squibb , Schering - Plough , Merck , and Eli - Lilly .", "label": "", "metadata": {}, "score": "73.31586"}
{"text": "10.1016/j.amjsurg.2004.04.002 .View Article PubMed .Halm EA , Lee C , Chassin MR : Is volume related to outcome in health care ?", "label": "", "metadata": {}, "score": "73.44148"}
{"text": "In addition , specific strategies are needed to improve appropriate use of antibiotic prophylaxis and sustainable implementation of hygiene guidelines to reduce infections .Electronic supplementary material .", "label": "", "metadata": {}, "score": "73.540794"}
{"text": "Patients in the two EPA - DHA groups received , on average , an additional amount of 223 ( \u00b162 ) mg EPA and 149 ( \u00b142 ) mg of DHA per day and those in the two groups of ALA 1.9 ( \u00b10.5 ) g / day .", "label": "", "metadata": {}, "score": "73.62906"}
{"text": "Some of the interventions have been familiar for decades , like protocols for hand hygiene and appropriate use of antibiotic prophylaxis .More research should be done to explore the barriers and drivers for sustainable implementation of patient safety interventions in health care .", "label": "", "metadata": {}, "score": "73.735466"}
{"text": "Warfarin Optimal Duration Italian Trial Investigators .N Engl J Med 2001 ; 345 : 165 -9 .Ridker PM , Goldhaber SZ , Danielson E , Rosenberg Y , Eby CS , Deitcher SR , et al .", "label": "", "metadata": {}, "score": "73.757614"}
{"text": "Patients allocated to placebo will receive a matching placebo tablet once daily .Detailed Description : .Within the US ' Johnson & Johnson Pharmaceutical Research & Development , L.L.C. ' is sponsor .", "label": "", "metadata": {}, "score": "73.76919"}
{"text": "PubMed .Soop M , Fryksmark U , Koster M , Haglund B : The incidence of adverse events in Swedish hospitals : a retrospective medical record review study .", "label": "", "metadata": {}, "score": "73.785675"}
{"text": "Treatment - emergent events and all events post randomization were reported .Treatment - emergent : after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication ( referred to as time window : 2 days ) .", "label": "", "metadata": {}, "score": "73.79578"}
{"text": "The modified Rankin score measures disability after stroke on a scale of 0 to 5 , at which the loss of independence in daily life begins at grade 2 .", "label": "", "metadata": {}, "score": "74.04216"}
{"text": "Anderson JL , Adams CD , Antman EM , Bridges CR , Califf RM , Casey DE Jr , et al .Circulation 2007 ; 116 : e148 -304 .", "label": "", "metadata": {}, "score": "74.10837"}
{"text": "In reproductive toxicology studies , pregnant rats received ticagrelor during organogenesis at doses from 20 to 300 mg / kg / day .The lowest dose was approximately the same as the MRHD of 90 mg twice daily for a 60 kg human on a mg / m2 basis .", "label": "", "metadata": {}, "score": "74.1797"}
{"text": "But in the absence of patient level data , this can not be explored in sufficient detail .Three studies included patients with provoked index VTE .", "label": "", "metadata": {}, "score": "74.1842"}
{"text": "Limitations of the study .Our study had several limitations .Firstly , the length of follow - up varied across studies .Trials assessing ASA and VKA had longer follow - up periods than studies evaluating new oral anticoagulants ( dabigatran , rivaroxaban , apixaban ) .", "label": "", "metadata": {}, "score": "74.20271"}
{"text": "Inadequate nasal intubation by tonsillectomy , resulting in tear off concha , bleeding and reoperation .Spinal anaesthesia in non - treated hypertension , resulting in hypotension , coma and contributed to death .", "label": "", "metadata": {}, "score": "74.28378"}
{"text": "All authors approved the manuscript for publication .AN is the guarantor .All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis .", "label": "", "metadata": {}, "score": "74.372"}
{"text": "Critical revision of the manuscript for important intellectual content : Cannegieter , Bollen , van der Meer , van der Wall , and Rosendaal .Statistical analysis : Torn , Cannegieter , and Rosendaal .", "label": "", "metadata": {}, "score": "74.525826"}
{"text": "After achieving non - inferiority , this trial also aims to establish superiority ( by means of hierarchical tests ) of dabigatran over warfarin .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double - Blind Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "74.567795"}
{"text": "[ Time Frame : For statistical analysis 1 : from randomisation to 6 months ( up to day 180 )For statistical analysis 2 : from randomisation to end of ptp , planned to be up to day 224 . ]", "label": "", "metadata": {}, "score": "74.68792"}
{"text": "Prospective cohort studies have provided evidence that the plant food - derived n-3 fatty acid \u03b1 - linolenic acid ( ALA ) may reduce fatal CHD ( 4 ) .", "label": "", "metadata": {}, "score": "74.779884"}
{"text": "Eur J Surg Oncol .2010 , 36 ( Suppl 1 ) : S27-S35 .View Article PubMed .N Engl J Med .", "label": "", "metadata": {}, "score": "74.78834"}
{"text": "Compared with placebo or observation , an increased risk of major bleeding was associated with the use of standard adjusted dose VKA , rivaroxaban , and low intensity VKA ( table 2 , web appendix 9 ) .", "label": "", "metadata": {}, "score": "74.85774"}
{"text": "Circulation 2002 ; 106 : 1622 -6 .James S , Akerblom A , Cannon CP , Emanuelsson H , Husted S , Katus H , et al .", "label": "", "metadata": {}, "score": "74.86041"}
{"text": "10.1136/bmj.326.7388.546 .PubMed Central View Article PubMed .Wilkinson TJ , Challis M , Hobma SO , Newble DI , Parboosingh JT , Sibbald RG , Wakeford R : The use of portfolios for assessment of the competence and performance of doctors in practice .", "label": "", "metadata": {}, "score": "74.87186"}
{"text": "Last reviewed on RxList : 9/18/2015This monograph has been modified to include the generic and brand name in many instances .WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert , MedlinePlus , Practice Guidelines , Scientific Statements , and scholarly medical literature .", "label": "", "metadata": {}, "score": "74.997635"}
{"text": "Implications for clinical practice .Taken together , our findings do not support strong recommendations to use aspirin in the primary prevention of cardiovascular events in all people with diabetes .", "label": "", "metadata": {}, "score": "75.04732"}
{"text": "Estimates differ from those reported in frequentist direct meta - analysis in ASPIRE and web appendix 5 ( both reported significant differences in favour of ASA ) because between study variance is treated as a constant in frequentist analyses .", "label": "", "metadata": {}, "score": "75.05194"}
{"text": "The surgeon reviewers classified the surgical AEs by clinical procedure involved , such as diagnostic process , surgical procedure , drug / fluid , medical procedure , other clinical management , discharge , and other .", "label": "", "metadata": {}, "score": "75.08002"}
{"text": "German Stroke Data Bank Collaborators , Assessment of functioning and disability after ischemic stroke .Stroke 2002;33 ( 8) 2053- 2059 PubMed Link to Article .", "label": "", "metadata": {}, "score": "75.16777"}
{"text": "German Stroke Data Bank Collaborators , Assessment of functioning and disability after ischemic stroke .Stroke 2002;33 ( 8) 2053- 2059 PubMed Link to Article .", "label": "", "metadata": {}, "score": "75.16777"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .The authors declare that they have no competing interests .", "label": "", "metadata": {}, "score": "75.18043"}
{"text": "The net clinical benefit seemed to favour the oral anticoagulants ( standard adjusted dose VKA , dabigatran , and apixaban ) when compared with placebo or observation and ASA ( fig 4 ) .", "label": "", "metadata": {}, "score": "75.38614"}
{"text": "Comparative risk of developing drug related side effects with aspirin compared with placebo or no treatment .Investigation of sources of heterogeneity .Heterogeneity by dose of aspirin , duration of treatment , compliance with treatment , and allocation concealment was explored by subgroup analysis .", "label": "", "metadata": {}, "score": "75.4323"}
{"text": "Fig 2 Cumulative incidence of cardiac catheterisation , percutaneous coronary intervention ( PCI ) and coronary artery bypass grafting ( CABG ) in patients intended for non - invasive management and randomised to ticagrelor or clopidogrel .", "label": "", "metadata": {}, "score": "75.44241"}
{"text": "A venous blood sample is taken in which the prothrombin time is measured .Prothrombin times are expressed as an INR .Laboratory procedures and materials do not change substantially during follow - up .", "label": "", "metadata": {}, "score": "75.48317"}
{"text": "Rates are shown for patients with a mechanical heart valve ( A ) , atrial fibrillation ( B ) , and myocardial infarction ( C ) .", "label": "", "metadata": {}, "score": "75.49728"}
{"text": "Low - dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial .JAMA 2008 ; 300 : 2134 -41 .", "label": "", "metadata": {}, "score": "75.89099"}
{"text": "The effects for ASA were more pronounced in the subgroup analysis than in the primary analysis ; however , they were still less favourable than both dosing strategies of VKA and dabigatran .", "label": "", "metadata": {}, "score": "76.070404"}
{"text": "Regional Differences .Results in the rest of the world compared to effects in North America ( US and Canada ) show a smaller effect in North America , numerically inferior to the control and driven by the US subset .", "label": "", "metadata": {}, "score": "76.101944"}
{"text": "In the absence of a placebo control , whether these are drug related can not be determined in most cases , except where they are more common on Ticagrelor or clearly related to the drug 's pharmacologic effect ( dyspnea ) .", "label": "", "metadata": {}, "score": "76.1164"}
{"text": "In a population of patients with acute coronary syndrome managed with a planned non - invasive treatment strategy , more intense P2Y12 receptor inhibition with ticagrelor achieved a clinically important reduction in ischaemic events and mortality , but without increasing major bleeding , compared with clopidogrel .", "label": "", "metadata": {}, "score": "76.32718"}
{"text": "Toxicity is to be explored further .Introduction . 1 2 3 4 5 6 Existing recommendations are primarily based on indirect evidence extrapolated from large trials of populations at high risk of cardiovascular events . 1 2 3 4 5 6 Evidence supporting the efficacy of aspirin therapy in trials of only people with diabetes is scant . 7 No significant reduction in the risk of major cardiovascular events with low dose aspirin compared with placebo was found in three additional trials published after that meta - analysis .", "label": "", "metadata": {}, "score": "76.550606"}
{"text": "10.1001/jama.294.22.2858 .View Article PubMed .Williams J : Risk management in surgery .Clinical Risk Management .Edited by : Vincent CA .", "label": "", "metadata": {}, "score": "76.60435"}
{"text": "No clinical trial has prospectively reported outcomes with P2Y12 inhibitors among patients intended for initial non - invasive management .What this study adds .In acute coronary syndrome patients initially intended for non - invasive management , ticagrelor achieved a clinically important reduction in ischaemic events and mortality compared with clopidogrel , without increasing major bleeding .", "label": "", "metadata": {}, "score": "76.6228"}
{"text": "Log in or register : .Download this article to citation manager .De Berardis Giorgia , Sacco Michele , Strippoli Giovanni F M , Pellegrini Fabio , Graziano Giusi , Tognoni Gianni et al .", "label": "", "metadata": {}, "score": "76.79167"}
{"text": "These will help clarify the role of aspirin in the primary prevention of cardiovascular disease in people with diabetes and may be pooled with existing data .", "label": "", "metadata": {}, "score": "77.10605"}
{"text": "Quality assessment of methods .Discrepancies in data extraction between the two reviewers were resolved by discussion and consensus , with an arbitrator .Statistical analysis .", "label": "", "metadata": {}, "score": "77.31987"}
{"text": "To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .For general information , see Learn About Clinical Studies .", "label": "", "metadata": {}, "score": "77.60905"}
{"text": "The weighting factor was the inverse of the probability of being included in the sample and was calculated by dividing the representation of a group in the population by the representation of this same group in the study sample [ 18 ] .", "label": "", "metadata": {}, "score": "77.74387"}
{"text": "The cumulative incidence of end points is shown in 1,014 patients with an MI and diabetes .Patients were randomly assigned to receive a margarine containing supplemental EPA combined with DHA , a margarine containing supplemental ALA , a margarine containing both EPA - DHA and ALA , or a placebo margarine .", "label": "", "metadata": {}, "score": "77.78196"}
{"text": "Am Heart J 2009 ; 157 : 599 -605 .Hirsch A , Windhausen F , Tijssen JG , Oude Ophuis AJ , van der Giessen WJ , van der Zee PM , et al .", "label": "", "metadata": {}, "score": "78.12996"}
{"text": "Requires medical intervention to stop or treat bleeding ( e.g. , epistaxis requiring visit to medical facility for packing ) .Minimal bleed .All others ( e.g. , bruising , bleeding gums , oozing from injection sites , etc . ) not requiring intervention or treatment .", "label": "", "metadata": {}, "score": "78.15288"}
{"text": "Extracranial major hemorrhage was defined as blood loss , inward or outward , leading to hospital admission for observation or treatment , or death .Bleeding events that occurred while the patient was already admitted for a different reason or admissions for diagnostic purposes only were not taken into account .", "label": "", "metadata": {}, "score": "78.21048"}
{"text": "Odd ratios for recurrence of VTE are below the diagonal line ( row defining treatment v column defining treatment ) ; odds ratios for major bleeding are above the diagonal line ( column defining treatment v row defining treatment ) .", "label": "", "metadata": {}, "score": "78.28645"}
{"text": "In patients with non - ST elevation acute coronary syndrome with moderate to high risk characteristics , current guidelines recommend an invasive strategy with angiography followed by percutaneous coronary intervention or coronary artery bypass grafting if appropriate . 1 A considerable proportion of patients do not have angiography or revascularisation during the initial hospital admission .", "label": "", "metadata": {}, "score": "78.415436"}
{"text": "Preventable surgical adverse events .Surgery taking place at the wrong site during kidney transplantectomy , resulting in an extra incision of the skin .Urosepsis after operation on femur fracture caused by non - indicated CAD .", "label": "", "metadata": {}, "score": "78.45054"}
{"text": "Early invasive versus selectively invasive management for acute coronary syndromes .N Engl J Med 2005 ; 353 : 1095 -104 .Amsterdam EA , Peterson ED , Ou FS , Newby LK , Pollack CV Jr , Gibler WB , et al .", "label": "", "metadata": {}, "score": "78.50677"}
{"text": "Moderate CYP3A inhibitors have lesser effects ( e.g. , diltiazem ) .CYP3A inducers ( e.g. , rifampin ) substantially reduce ticagrelor blood levels .P - gp inhibitors ( e.g. cyclosporine ) increase ticagrelor exposure .", "label": "", "metadata": {}, "score": "78.52232"}
{"text": "The onset of IPA was evaluated on Day 1 of the study following loading doses of 180 mg ticagrelor or 600 mg clopidogrel .As shown in Figure 2 , IPA was higher in the ticagrelor group at all time points .", "label": "", "metadata": {}, "score": "78.59541"}
{"text": "The onset of IPA was evaluated on Day 1 of the study following loading doses of 180 mg ticagrelor or 600 mg clopidogrel .As shown in Figure 2 , IPA was higher in the ticagrelor group at all time points .", "label": "", "metadata": {}, "score": "78.59541"}
{"text": "\u00a9 Zegers et al ; licensee BioMed Central Ltd. 2011 .This article is published under license to BioMed Central Ltd. Abstract .Objective To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease .", "label": "", "metadata": {}, "score": "78.597916"}
{"text": "The onset of IPA was evaluated on Day 1 of the study following loading doses of 180 mg ticagrelor or 600 mg clopidogrel .As shown in Figure 3 , IPA was higher in the ticagrelor group at all time points .", "label": "", "metadata": {}, "score": "78.612335"}
{"text": "Arch Intern Med 1998 ; 158 : 585 -93 .Anderson FA Jr , Wheeler HB , Goldberg RJ , Hosmer DW , Patwardhan NA , Jovanovic B , et al .", "label": "", "metadata": {}, "score": "78.98477"}
{"text": "Stone S , Teare L , Cookson B : Guiding hands of out teachers .Hand - hygiene Liaison Group .Lancet .View Article PubMed .", "label": "", "metadata": {}, "score": "79.04002"}
{"text": "Although further studies need to establish the benefit - harm balance of ASA compared with VKA and the new oral anticoagulants , ASA use for secondary prevention of recurrent VTE may be valuable in patients with arterial disease who are at low to moderate risk of recurrent VTE .", "label": "", "metadata": {}, "score": "79.07284"}
{"text": "Sudden death was extended with placement of cardioverter defibrillators because ventricular arrhythmias are the main cause of sudden death and cardioverter defibrillators are implanted in patients who are at high risk for developing ventricular arrhythmias ( 16 , 17 ) .", "label": "", "metadata": {}, "score": "79.36077"}
{"text": "28 29 We also conducted fixed and random effects models with vague priors .Assessment of model fit was based on comparison of residual deviance to the number of unconstrained data points and assessment of the deviance information criterion .", "label": "", "metadata": {}, "score": "79.399376"}
{"text": "Serum Creatinine : .The increases typically did not progress with ongoing treatment and often decreased with continued therapy .Evidence of reversibility upon discontinuation was observed even in those with the greatest on treatment increases .", "label": "", "metadata": {}, "score": "79.39992"}
{"text": "HM and PPG have been involved in revising the article critically for important intellectual content .GW contributed to the design and conception of the study and has been involved in revising the article critically for important intellectual content .", "label": "", "metadata": {}, "score": "79.44543"}
{"text": "Medication was coded according to the Anatomical Therapeutic Chemical ( ATC ) Classification System ( World Health Organization , 2009 ) , including ATC code A10 for antidiabetic medication .", "label": "", "metadata": {}, "score": "79.44999"}
{"text": "View Article PubMed .NVZ , Orde van medisch specialisten , LEVV , V&VN , NFU : Patient safety campaign : prevent adverse events , work safe in Dutch hospitals .", "label": "", "metadata": {}, "score": "79.499115"}
{"text": "Mutagenesis .Ticagrelor did not demonstrate genotoxicity when tested in the Ames bacterial mutagenicity test , mouse lymphoma assay and the rat micronucleus test .The active O - demethylated metabolite did not demonstrate genotoxicity in the Ames assay and mouse lymphoma assay .", "label": "", "metadata": {}, "score": "79.505066"}
{"text": "The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians .The AMA designates this journal - based CME activity for a maximum of 1 AMA PRA Category 1 Credit TM per course .", "label": "", "metadata": {}, "score": "79.57393"}
{"text": "No dosage adjustment is needed in patients with renal impairment .Patients receiving dialysis have not been studied [ see Clinical Pharmacology .Hepatic Impairment .", "label": "", "metadata": {}, "score": "79.66167"}
{"text": "Ann Intern Med .View Article PubMed .Gooiker GA , van Gijn W , Post PN , van de Velde CJ , Tollenaar RA , Wouters MW : A systematic review and meta - analysis of the volume - outcome relationship in the surgical treatment of breast cancer .", "label": "", "metadata": {}, "score": "79.79315"}
{"text": "Information and communication ( improving available sources of information , communication structures and medical record keeping ) .Application of aviation - style crew resource management to improve teamwork [ 37 ] .", "label": "", "metadata": {}, "score": "79.8056"}
{"text": "Patients can be transitioned from clopidogrel to ticagrelor without interruption of antiplatelet effect [ see dosage and Administration ( 2 ) .Structure .Ticagrelor cyclopentyltriazolopyrimidine , inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP - receptor .", "label": "", "metadata": {}, "score": "79.88202"}
{"text": "Netherlands Health Care Inspectorate .References .CMAJ .10.1503/cmaj.1040498 .PubMed Central View Article PubMed .Brennan TA , Leape LL , Laird NM , Hebert L , Localio AR , Lawthers AG , Newhouse JP , Weiler PC , Hiatt HH : Incidence of adverse events and negligence in hospitalized patients .", "label": "", "metadata": {}, "score": "80.002106"}
{"text": "The percentage of smokers was highest in the placebo group and lowest in the EPA - DHA plus ALA group .n-3 Fatty acid supplementation and compliance .", "label": "", "metadata": {}, "score": "80.0071"}
{"text": "Lancet 2010 ; 375 : 283 -93 .Simoons ML .Effect of glycoprotein IIb / IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation : the GUSTO IV - ACS randomised trial .", "label": "", "metadata": {}, "score": "80.21647"}
{"text": "Lancet .10.1016/S0140 - 6736(00)02814 - 2 .View Article PubMed .Baba - Akbari Sari A , Sheldon TA , Cracknell A , Turnbull A : Sensitivity of routine system for reporting patient safety incidents in an NHS hospital : retrospective patient case note review .", "label": "", "metadata": {}, "score": "80.275345"}
{"text": "Administrative , technical , and material support : van der Meer and Rosendaal .Study supervision : Bollen , van der Meer , and Rosendaal .", "label": "", "metadata": {}, "score": "80.31163"}
{"text": "In vitro metabolism studies demonstrate that ticagrelor and its major active metabolite are weak inhibitors of CYP3A4 , potential activators of CYP3A5 and inhibitors of the P - gp transporter .", "label": "", "metadata": {}, "score": "80.46782"}
{"text": "Also the inadequate application of new techniques , such as endoscopic procedures , and procedures that demand specific expertise and experience , for example vessel surgery , resulted in AEs .", "label": "", "metadata": {}, "score": "80.53967"}
{"text": "The primary route of elimination for the major metabolite of ticagrelor is most likely to be biliary secretion .The mean t\u00bd is approximately 7 hours for ticagrelor and 9 hours for the active metabolite .", "label": "", "metadata": {}, "score": "80.585785"}
{"text": "Vitamin K antagonists , at a standard adjusted dose , was associated with the greatest risk reduction in recurrent venous thromboembolism but also with the greatest risk of major bleeding .", "label": "", "metadata": {}, "score": "80.85525"}
{"text": "Incisional hernia after laparotomy resulting in readmission and reoperation .Infection tissue expander head , resulting in a readmission , operative removal and a reconstructive procedure .", "label": "", "metadata": {}, "score": "80.92288"}
{"text": "Financial support was obtained from the Netherlands Heart Foundation , the National Institutes of Health ( NIH ) , and Unilever Research and Development .The grant of the Netherlands Heart Foundation covered baseline examinations and mortality follow - up .", "label": "", "metadata": {}, "score": "80.97264"}
{"text": "As shown in Figure 3 , mean maximum IPA following the last dose of ticagrelor was 88 % and 62 % for clopidogrel .After 5 days , IPA in the ticagrelor group was similar to IPA in the placebo group .", "label": "", "metadata": {}, "score": "81.05525"}
{"text": "As shown in Figure 3 , mean maximum IPA following the last dose of ticagrelor was 88 % and 62 % for clopidogrel .After 5 days , IPA in the ticagrelor group was similar to IPA in the placebo group .", "label": "", "metadata": {}, "score": "81.05525"}
{"text": "This is also in accord with the results of animal experiments suggesting that ALA , EPA , and DHA have similar antiarrhythmic effects by influencing the Na + and L - type Ca 2 + channels of cardiomyocytes ( 5 ) .", "label": "", "metadata": {}, "score": "81.080475"}
{"text": "A daily maintenance dose of aspirin 75 - 100 mg was recommended , but higher maintenance doses of aspirin were allowed according to local judgment .", "label": "", "metadata": {}, "score": "81.10101"}
{"text": "A daily maintenance dose of aspirin 75 - 100 mg was recommended , but higher maintenance doses of aspirin were allowed according to local judgment .", "label": "", "metadata": {}, "score": "81.10101"}
{"text": "As shown in Figure 4 , mean maximum IPA following the last dose of ticagrelor was 88 % and 62 % for clopidogrel .After 5 days , IPA in the ticagrelor group was similar to IPA in the placebo group .", "label": "", "metadata": {}, "score": "81.10502"}
{"text": "Lancet 2009 ; 373 : 1849 -60 .Berger JS , Roncaglioni MC , Avanzini F , Pangrazzi I , Tognoni G , Brown DL .", "label": "", "metadata": {}, "score": "81.43583"}
{"text": "a For the components , the first - occurring component of the composite is included .b The number of first events for the components CV Death , MI and Stroke are the actual number of first events for each component and do not add up to the number of events in the composite endpoint .", "label": "", "metadata": {}, "score": "81.481766"}
{"text": "The primary route of elimination for the major metabolite of ticagrelor is most likely to be biliary secretion .The mean t1/2 is approximately 7 hours for ticagrelor and 9 hours for the active metabolite .", "label": "", "metadata": {}, "score": "81.59277"}
{"text": "There are no adequate and well - controlled studies of ticagrelor use in pregnant women .In animal studies , ticagrelor caused structural abnormalities at maternal doses about 5 to 7 times the maximum recommended human dose ( MRHD ) based on body surface area .", "label": "", "metadata": {}, "score": "81.60055"}
{"text": "Subgroup analysis of sources of variability for outcomes analysed .Values are relative risks ( 95 % confidence intervals ) and number of studies .We also explored heterogeneity by sex .", "label": "", "metadata": {}, "score": "81.68217"}
{"text": "van der Schaaf TW , Habraken MMP : PRISMA - Medical : a brief description .2005 , Eindhoven : Eindhoven University of Technology .Smits M , Zegers M , Wagner C , Timmermans DRM , Zwaan L , van der Wal G , Groenewegen PP : Exploring the causes of adverse events in hospitals and potential prevention strategies .", "label": "", "metadata": {}, "score": "81.7258"}
{"text": "PubMed Central View Article PubMed .Wilson RM , Runciman WB , Gibberd RW , Harrison BT , Newby L , Hamilton JD : The Quality in Australian Health Care Study .", "label": "", "metadata": {}, "score": "81.838806"}
{"text": "Higher doses do not have an established benefit in the ACS setting , and there is a strong suggestion that use of such doses reduces the effectiveness of Brilinta .", "label": "", "metadata": {}, "score": "81.88069"}
{"text": "Despite the need to treat such results cautiously , there appears to be good reason to restrict aspirin maintenance dosage accompanying ticagrelor to 100 mg .", "label": "", "metadata": {}, "score": "81.986145"}
{"text": "28 29 30 31 Assuming a relative risk reduction associated with aspirin treatment of about 10 % , as suggested by our meta - analysis , 1000 people need to be treated for one year to prevent one or two major cardiovascular events .", "label": "", "metadata": {}, "score": "82.02214"}
{"text": "Because many drugs are excreted in human milk , and because of the potential for serious adverse reactions in nursing infants from ticagrelor , a decision should be made whether to discontinue nursing or to discontinue drug , taking into account the importance of the drug to the mother .", "label": "", "metadata": {}, "score": "82.02218"}
{"text": "Strong CYP3A inhibitors ( e.g. , ketoconazole , itraconazole , and clarithromycin ) substantially increase ticagrelor exposure .Moderate CYP3A inhibitors have lesser effects ( e.g. , diltiazem ) .", "label": "", "metadata": {}, "score": "82.17163"}
{"text": "Several registries and clinical trials have shown that 30 - 60 % of patients admitted with non - ST elevation acute coronary syndrome in the Western world do not actually have cardiac catheterisation during hospital admission and 45 - 80 % of patients do not have revascularisation .", "label": "", "metadata": {}, "score": "82.17848"}
{"text": "The safety and effectiveness of ticagrelor in pediatric patients have not been established .Geriatric Use .The relative risk of bleeding was similar in both treatment and age groups .", "label": "", "metadata": {}, "score": "82.35014"}
{"text": "10.1136/qshc.2005.016964 .PubMed Central View Article PubMed .Aggarwal R , Ward J , Balasundaram I , Sians P , Athanasiou T , Darzi A : Proving the effectiveness of virtual reality simulation for training in laparoscopic surgery .", "label": "", "metadata": {}, "score": "82.850876"}
{"text": "Ticagrelor and its active metabolite are approximately equipotent .The inhibition of platelet aggregation ( IPA ) by ticagrelor and clopidogrel was compared in a 6 week study examining both acute and chronic platelet inhibition effects in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "83.03046"}
{"text": "10.1093/intqhc/14.4.269 .View Article PubMed .World alliance for patient safety : The second global patient safety challenge .Safe surgery saves lives .", "label": "", "metadata": {}, "score": "83.124374"}
{"text": "Exclusion Criteria : .Patients in whom anticoagulant treatment for their index PE or DVT should be continued .Childbearing potential without proper contraceptive measures , pregnancy or breast feeding .", "label": "", "metadata": {}, "score": "83.19072"}
{"text": "Please refer to The JAMA Network 's Privacy Policy for additional information .Torn M , Cannegieter SC , Bollen WM , van der Meer FM , van der Wall EE , Rosendaal FR .", "label": "", "metadata": {}, "score": "83.25639"}
{"text": "We used the intention to treat principle and SAS version 9.2 for all analyses .We used a P value of 0.05 as a critical value determining statistical significance of the overall treatment differences .", "label": "", "metadata": {}, "score": "83.39373"}
{"text": "Effects of intensive blood - pressure lowering and low - dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment ( HOT ) randomised trial .", "label": "", "metadata": {}, "score": "83.45435"}
{"text": "Conclusions .Surgical AEs occur more often than other types of AEs , are more often preventable and their consequences are more severe .Therefore , surgical AEs have a major impact on the burden of AEs during hospitalizations .", "label": "", "metadata": {}, "score": "83.53926"}
{"text": "Both the 60 mg and 90 mg regimens of BRILINTA in combination with aspirin were superior to aspirin alone in reducing the incidence of CV death , MI or stroke .", "label": "", "metadata": {}, "score": "83.71305"}
{"text": "American Heart Association ; American Diabetes Association .Primary prevention of cardiovascular diseases in people with diabetes mellitus : a scientific statement from the American Heart Association and the American Diabetes Association .", "label": "", "metadata": {}, "score": "83.83699"}
{"text": "Ticagrelor and AR - C124910XX were shown to have no inhibitory effect on human CYP1A2 , CYP2C19 , and CYP2E1 activity .For specific in vivo effects on the pharmacokinetics of simvastatin , atorvastatin , ethinyl estradiol , levonorgesterol , tolbutamide , digoxin and cyclosporine , see Figure 6 .", "label": "", "metadata": {}, "score": "84.1763"}
{"text": "In a prenatal / postnatal study , pregnant rats received ticagrelor at doses of 10 to 180 mg / kg / day during late gestation and lactation .", "label": "", "metadata": {}, "score": "84.18642"}
{"text": "Ingestion of a high - fat meal had no effect on ticagrelor Cmax , but resulted in a 21 % increase in AUC .The Cmax of its major metabolite was decreased by 22 % with no change in AUC .", "label": "", "metadata": {}, "score": "84.28703"}
{"text": "Excretion .The primary route of ticagrelor elimination is hepatic metabolism .When radiolabeled ticagrelor is administered , the mean recovery of radioactivity is approximately 84 % ( 58 % in feces , 26 % in urine ) .", "label": "", "metadata": {}, "score": "84.353195"}
{"text": "Excretion .The primary route of ticagrelor elimination is hepatic metabolism .When radiolabeled ticagrelor is administered , the mean recovery of radioactivity is approximately 84 % ( 58 % in feces , 26 % in urine ) .", "label": "", "metadata": {}, "score": "84.353195"}
{"text": "Figure 4 - Impact of intrinsic factors on the pharmacokinetics of ticagrelor .Habitual smoking increased population mean clearance of ticagrelor by approximately 22 % when compared to non - smokers .", "label": "", "metadata": {}, "score": "84.650955"}
{"text": "When possible , discontinue ticagrelor at least 5 days prior to any surgery .Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography , percutaneous coronary intervention ( PCI ) , CABG , or other surgery .", "label": "", "metadata": {}, "score": "84.68158"}
{"text": "View Article PubMed .N Engl J Med .10.1056/NEJMsa0911535 .View Article PubMed . de Vries EN , Dijkstra L , Smorenburg SM , Meijer RP , Boermeester MA : The SURgical PAtient Safety System ( SURPASS ) checklist optimizes timing of antibiotic prophylaxis .", "label": "", "metadata": {}, "score": "84.70822"}
{"text": "Figure 5 : Impact of intrinsic factors on the pharmacokinetics of ticagrelor .Effects of Other Drugs on BRILINTA .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .", "label": "", "metadata": {}, "score": "84.730896"}
{"text": "Correspondence : Frits R. Rosendaal , MD , PhD , Department of Clinical Epidemiology , Leiden University Medical Center , Building 1 , C7-P , PO Box 9600 , 2300 RC Leiden , the Netherlands ( f.r.rosendaal@lumc.nl ) .", "label": "", "metadata": {}, "score": "84.749"}
{"text": "The offset of IPA was examined after 6 weeks on ticagrelor 90 mg twice daily or clopidogrel 75 mg daily , again in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "84.84106"}
{"text": "The offset of IPA was examined after 6 weeks on ticagrelor 90 mg twice daily or clopidogrel 75 mg daily , again in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "84.84106"}
{"text": "The offset of IPA was examined after 6 weeks on ticagrelor 90 mg twice daily or clopidogrel 75 mg daily , again in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "84.84106"}
{"text": "If your institution uses Athens or Shibboleth authentication , please contact your site administrator to receive your user name and password .What is this ?", "label": "", "metadata": {}, "score": "84.87239"}
{"text": "PubMed Central View Article PubMed .Awad SS , Fagan SP , Bellows C , Albo D , Green - Rashad B , Garza De la M , Berger DH : Bridging the communication gap in the operating room with medical team training .", "label": "", "metadata": {}, "score": "85.030624"}
{"text": "Ticagrelor was given in a loading dose of 180 mg followed by 90 mg twice daily .Patients randomised to clopidogrel who had not received an open label loading dose and had not been taking clopidogrel for at least five days before randomisation received a 300 mg loading dose of clopidogrel study drug followed by 75 mg daily .", "label": "", "metadata": {}, "score": "85.44675"}
{"text": "16 17 18 19 20 These alternatives may offer a simplified approach to anticoagulation and a better harm profile than VKA .We performed a systematic review and network meta - analysis of the literature to quantify , summarise , and compare the rates of recurrent VTE and major bleeding episodes for antiplatelet drugs and different anticoagulant agents for the secondary prevention of recurrent VTE .", "label": "", "metadata": {}, "score": "85.59677"}
{"text": "BLEEDING RISK , and ( B ) ASPIRIN DOSE AND Brilinta EFFECTIVENESS .See full prescribing information for complete boxed warning .Condition Name : .", "label": "", "metadata": {}, "score": "85.953186"}
{"text": "Standard adjusted dose VKA , dabigatran , rivaroxaban and apixaban ( both 2.5 mg and 5 mg twice daily ) seemed to be associated with a reduced risk of recurrence compared with ASA .", "label": "", "metadata": {}, "score": "86.075356"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "86.076096"}
{"text": "JHC declares consulting fees from Eli Lilly and Pfizer .JH is an employee of AstraZeneca and has equity ownership in AstraZeneca .SH declares research grants from AstraZeneca , Bristol - Myers Squibb , Pfizer , and Bayer and consultant fees from Sanofi - Aventis , Pfizer , and AstraZeneca .", "label": "", "metadata": {}, "score": "86.30747"}
{"text": "Log in or register : .Download this article to citation manager .Castellucci Lana A , Cameron Chris , Le Gal Gr\u00e9goire , Rodger Marc A , Coyle Doug , Wells Philip S et al .", "label": "", "metadata": {}, "score": "86.43261"}
{"text": "Thromboembolism Venous Thromboembolism Venous Thrombosis Cardiovascular Diseases Embolism and Thrombosis Thrombosis Vascular Diseases Dabigatran Warfarin .Anticoagulants Antithrombins Enzyme Inhibitors Hematologic Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protease Inhibitors Serine Proteinase Inhibitors Therapeutic Uses Abstract .", "label": "", "metadata": {}, "score": "87.42042"}
{"text": "P - gp inhibitors ( e.g. , cyclosporine ) increase ticagrelor exposure .Figure 6 : Effect of co - administered drugs on the pharmacokinetics of ticagrelor .", "label": "", "metadata": {}, "score": "87.511505"}
{"text": "We need to know the scale and underlying causes of surgical adverse events ( AEs ) in order to improve the safety of care in surgical units .", "label": "", "metadata": {}, "score": "87.82298"}
{"text": "Ann Intern Med 2008 ; 149 : 698 -707 .Kahn SR , Shbaklo H , Lamping DL , Holcroft CA , Shrier I , Miron MJ , et al .", "label": "", "metadata": {}, "score": "87.971954"}
{"text": "Stopping ticagrelor increases the risk of subsequent cardiovascular events .The following adverse reactions are also discussed elsewhere in the labeling : Warnings .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice .", "label": "", "metadata": {}, "score": "88.18337"}
{"text": "The combined effects of EPA - DHA and ALA on the two composite end points are compatible with additive effects of either EPA - DHA or ALA .", "label": "", "metadata": {}, "score": "88.25952"}
{"text": "Am Heart J 2009 ; 158 : 748 -54 .Budaj A , Yusuf S , Mehta SR , Fox KA , Tognoni G , Zhao F , et al .", "label": "", "metadata": {}, "score": "88.67346"}
{"text": "Patients can be transitioned from clopidogrel to BRILINTA without interruption of antiplatelet effect [ see DOSAGE AND ADMINISTRATION ] .Pharmacokinetics .Ticagrelor demonstrates dose proportional pharmacokinetics , which are similar in patients and healthy volunteers .", "label": "", "metadata": {}, "score": "88.80431"}
{"text": "Using the terms diabetes mellitus and aspirin and a filter highly sensitive for randomised controlled trials only , we searched Medline ( 1966-November 2008 ) for trials of people with diabetes who received aspirin .", "label": "", "metadata": {}, "score": "88.8363"}
{"text": "The Dutch Patient Safety Research Program has been initiated by the Dutch Order of Medical Specialists with financial support from the Ministry of Health , Welfare and Sport .", "label": "", "metadata": {}, "score": "89.2733"}
{"text": "Patients can be transitioned from clopidogrel to ticagrelor without interruption of antiplatelet effect [ see dosage and Administration ( 2 ) .Pharmacokinetics .Ticagrelor demonstrates dose proportional pharmacokinetics , which are similar in patients and healthy volunteers .", "label": "", "metadata": {}, "score": "89.36417"}
{"text": "In the Netherlands , all outpatients who are treated with vitamin K antagonists are referred to regional anticoagulation clinics to have their treatment monitored .Patients visit the anticoagulation clinic regularly or are visited at home .", "label": "", "metadata": {}, "score": "89.53505"}
{"text": "Once - Daily Oral Direct Factor XaInhibitor Rivaroxaban In The Long - Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep - Vein Thrombosis Or Pulmonary Embolism .", "label": "", "metadata": {}, "score": "90.02348"}
{"text": "Diabetes alters smooth muscle function through atherosclerotic lesion formation , plaque instability , and cardiovascular events .Basic research shows that peroxisome proliferator - activated receptor \u03b3 ( PPAR - \u03b3 ) plays a critical role in the regulation of insulin sensitivity .", "label": "", "metadata": {}, "score": "90.29651"}
{"text": "What is already known on this topic .People with diabetes are at an increased risk of cardiovascular disease than those without diabetes .Most guidelines recommend the use of aspirin in the primary prevention of major cardiovascular events in people with diabetes .", "label": "", "metadata": {}, "score": "90.59424"}
{"text": "Distribution .Metabolism .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .Ticagrelor and its major active metabolite are weak P - glycoprotein substrates and inhibitors .", "label": "", "metadata": {}, "score": "90.61757"}
{"text": "Distribution .Metabolism .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .Ticagrelor and its major active metabolite are weak P - glycoprotein substrates and inhibitors .", "label": "", "metadata": {}, "score": "90.61757"}
{"text": "Absorption of ticagrelor occurs with a median tmax of 1.5 h ( range 1.0 - 4.0 ) .The formation of the major circulating metabolite AR - C124910XX ( active ) from ticagrelor occurs with a median tmax of 2.5 h ( range 1.5 - 5.0 ) .", "label": "", "metadata": {}, "score": "90.747475"}
{"text": "Only content that has not been published , posted , or submitted elsewhere should be submitted .By submitting this Comment , you and any coauthors transfer copyright to the journal if your Comment is posted .", "label": "", "metadata": {}, "score": "90.89519"}
{"text": "CLINICAL PHARMACOLOGY .Mechanism Of Action .Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP - receptor to prevent signal transduction and platelet activation .", "label": "", "metadata": {}, "score": "90.90245"}
{"text": "Access to the PDF is only available via article purchase .", "label": "", "metadata": {}, "score": "90.94914"}
{"text": "Ticagrelor is metabolized by the liver and impaired hepatic function can increase risks for bleeding and other adverse events .Hence , ticagrelor is contraindicated for use in patients with severe hepatic impairment and its use should be considered carefully in patients with moderate hepatic impairment .", "label": "", "metadata": {}, "score": "91.585144"}
{"text": "As shown in Table 1 , Ticagrelor was associated with a somewhat greater risk of non-CABG bleeding than was Clopidogrel .No baseline demographic factor altered the relative risk of bleeding with Ticagrelor compared to Clopidogrel .", "label": "", "metadata": {}, "score": "91.684845"}
{"text": "Unilever markets food products , some of which are enriched in omega-3 fatty acids .No other potential conflicts of interest relevant to this article were reported .", "label": "", "metadata": {}, "score": "91.69427"}
{"text": "Official Title : .Once - daily Oral Direct Factor XaInhibitor Rivaroxaban in the Long - term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep - vein Thrombosis or Pulmonary Embolism .", "label": "", "metadata": {}, "score": "91.76318"}
{"text": "Standard adjusted dose VKA had the highest absolute risk difference and ASA the lowest absolute risk difference ( table 2 ) .Standard adjusted dose VKA and dabigatran were associated with the highest probability of being the best therapy ( 66 % and 17 % , respectively ) among all treatments ( web appendix 4 ) .", "label": "", "metadata": {}, "score": "91.86953"}
{"text": "All authors read and have approved the final manuscript .Authors ' Affiliations .NIVEL , Netherlands Institute for Health Services Research .EMGO Institute , Department of Public and Occupational Health , VU University Medical Centre ( VUmc ) .", "label": "", "metadata": {}, "score": "91.93622"}
{"text": "Contraindications to anticoagulant therapy .Patients who in the investigators opinion should not be treated with warfarin .Allergy to heparins or other alternate approved therapy used for initial treatment , warfarin or dabigatran , or to one of the excipients included in these medications .", "label": "", "metadata": {}, "score": "92.155975"}
{"text": "After the initial loading dose of aspirin ( usually 325 mg ) , use ticagrelor with a daily maintenance dose of aspirin of 75 - 100 mg .", "label": "", "metadata": {}, "score": "92.4677"}
{"text": "Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes ( ACCEPT - D ) : design of a randomized study of the efficacy of low - dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins .", "label": "", "metadata": {}, "score": "93.50845"}
{"text": "Effects of Other Drugs on Ticagrelor .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .The effects of other drugs on the pharmacokinetics of ticagrelor are presented in Figure 5 as change relative to ticagrelor given alone ( test / reference ) .", "label": "", "metadata": {}, "score": "93.5167"}
{"text": "The mean absolute bioavailability of ticagrelor is about 36 % ( range 30%-42 % ) .Ingestion of a high - fat meal had no effect on ticagrelor Cmax , but resulted in a 21 % increase in AUC .", "label": "", "metadata": {}, "score": "94.20906"}
{"text": "10.1093/intqhc / mzp025 .PubMed Central View Article PubMed .Int J Qual Health Care .10.1093/intqhc / mzp047 .View Article PubMed .", "label": "", "metadata": {}, "score": "94.38231"}
{"text": "Ticagrelor , like other antiplatelet agents , can cause significant , sometimes fatal bleeding .Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage .", "label": "", "metadata": {}, "score": "94.56497"}
{"text": "Pharmacodynamics .The inhibition of platelet aggregation ( IPA ) by ticagrelor and clopidogrel was compared in a 6 week study examining both acute and chronic platelet inhibition effects in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "95.69937"}
{"text": "Pharmacodynamics .The inhibition of platelet aggregation ( IPA ) by ticagrelor and clopidogrel was compared in a 6 week study examining both acute and chronic platelet inhibition effects in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "95.69937"}
{"text": "By using it you agree that that you are requesting the material solely for personal , non - commercial use , and that it is subject to the AMA 's Terms of Use .", "label": "", "metadata": {}, "score": "95.73464"}
{"text": "Immunocompromised Patients .There is no FDA guidance one the use of Ticagrelor in patients who are immunocompromised .Administration and Monitoring .Administration .[ [ Orall .", "label": "", "metadata": {}, "score": "96.629295"}
{"text": "See Pharmacology .Other Concomitant Therapy .Ticagrelor can be administered with unfractionated or low - molecular - weight heparin , GPIIb / IIIa inhibitors , proton pump inhibitors , beta - blockers , angiotensin converting enzyme inhibitors , and angiotensin receptor blockers .", "label": "", "metadata": {}, "score": "97.03692"}
{"text": "Arch Intern Med .doi:10.1001/archinternmed.2009.176 .Athens and Shibboleth are access management services that provide single sign - on to protected resources .They replace the multiple user names and passwords necessary to access subscription - based content with a single user name and password that can be entered once per session .", "label": "", "metadata": {}, "score": "97.6134"}
{"text": "Stopping ticagrelor increases the risk of subsequent cardiovascular events .WARNING : ( A )BLEEDING RISK , and ( B ) ASPIRIN DOSE AND ticagrelor EFFECTIVENESS .", "label": "", "metadata": {}, "score": "98.500084"}
{"text": "How Supplied .Brilinta ( ticagrelor ) 90 mg is supplied as a round , biconvex , yellow , film - coated tablet marked with a \" 90 \" above \" T \" on one side .", "label": "", "metadata": {}, "score": "99.40771"}
{"text": "BRILINTA can be taken with or without food .Absorption of ticagrelor occurs with a median tmax of 1.5 h ( range 1.0- 4.0 ) .", "label": "", "metadata": {}, "score": "101.14371"}
{"text": "ticagrelor can be administered with or without food .A patient who misses a dose of ticagrelor should take one 90 mg tablet ( their next dose ) at its scheduled time .", "label": "", "metadata": {}, "score": "102.40233"}
{"text": "10.1007/s10238 - 006 - 0116 - 5 .View Article PubMed .Institute of Medicine : To err is human : building a safer health system .", "label": "", "metadata": {}, "score": "102.808266"}
{"text": "10.1046/j.1365 - 2168.1998.00883.x .View Article PubMed .The Netherlands Health Care Inspectorate : Standardisation crucial for risk reduction in operative procedures ( in Dutch ) .", "label": "", "metadata": {}, "score": "103.190216"}
{"text": "WikiDoc does not promote any medication or off - label use of drugs .Please read our full disclaimer here .Black Box Warning .FDA Package Insert for Ticagrelor contains no information regarding Black Box Warning .", "label": "", "metadata": {}, "score": "104.12825"}
{"text": "Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage .Do not start ticagrelor in patients planned to undergo urgent coronary artery bypass graft surgery ( CABG ) .", "label": "", "metadata": {}, "score": "109.70321"}
{"text": "Gender .There is no FDA guidance on the use of Ticagrelor with respect to specific gender populations .Race .There is no FDA guidance on the use of Ticagrelor with respect to specific racial populations .", "label": "", "metadata": {}, "score": "113.80472"}
{"text": "There is limited information about Labor and Delivery of Ticagrelor tablet in patients .Nursing Mothers .There is limited information about Nursing Mothers of Ticagrelor tablet in patients .", "label": "", "metadata": {}, "score": "118.085205"}
{"text": "The chemical structure of ticagrelor is : .Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10 \u03bcg / mL at room temperature .", "label": "", "metadata": {}, "score": "122.78548"}
